Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors by O'Dowd, Colin et al.
Identification and Structure-Guided Development of Pyrimidinone
Based USP7 Inhibitors
O'Dowd, C., Helm, M., rountree, S., Flasz, J. T., Arkoudis, E., miel, H., ... Harrison, T. (2018). Identification and
Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors. ACS MEDICINAL CHEMISTRY
LETTERS, 9(3), 238-243. https://doi.org/10.1021/acsmedchemlett.7b00512
Published in:
ACS MEDICINAL CHEMISTRY LETTERS
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2018 American Chemical Society.
This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
 Identification and Structure-Guided Development of Pyrimidinone 
Based USP7 Inhibitors 
Colin R. O’Dowd†*, Matthew D. Helm†, J. S. Shane Rountree†, Jakub T. Flasz‡§, Elias Arkoudis‡§, Hu-
gues Miel†, Peter R. Hewitt†, Linda Jordan†§, Oliver Barker†, Caroline Hughes†, Ewelina Rozycka†, 
Eamon Cassidy†, Keeva McClelland†§, Ewa Odrzywol†§, Natalie Page†, Stephanie Feutren-Burton†, 
Scarlett Dvorkin‡, Gerald Gavory†, Timothy Harrison†‡. 
†Almac Discovery Ltd, Centre for Precision Therapeutics, 97 Lisburn Road, Belfast, Northern Ireland BT9 7AE, United 
Kingdom. ‡Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland BT9 7AE, United 
Kingdom. 
KEYWORDS USP7 ubiquitination deubiquitinase HAUSP p53 Mdm2 proteasome ubiquitin 
ABSTRACT: Ubiquitin specific protease 7 (USP7, HAUSP) has become an attractive target in drug discovery due to the role it plays 
in modulating Mdm2 levels and consequently p53. Increasing interest in USP7 is emerging due to its potential involvement in onco-
genic pathways as well as possible roles in both metabolic and immune disorders in addition to viral infections. Potent, novel and 
selective inhibitors of USP7 have been developed using both rational and structure-guided design enabled by high resolution co-
crystallography. Initial hits were identified via fragment-based screening, scaffold-hopping and hybridization exercises. Two distinct 
sub-series are described along with associated SAR trends, as are initial efforts aimed at developing compounds suitable for in vivo 
experiments. Overall these discoveries will enable further research into the wider biological role of USP7.
The process of protein ubiquitination is a central tenet of the 
ubiquitin proteasome system (UPS) and is crucial in many fun-
damental cellular processes such as proteolysis, cell-cycle con-
trol, DNA repair and apoptosis.1,2  The importance of this path-
way in controlling such key cellular processes cannot be under-
stated and increasing evidence linking the UPS to human dis-
eases such as cancer3 and neurodegenerative disorders4 is 
emerging. The approved proteasome inhibitor Velcade® 
(bortezimib) has demonstrated that the UPS is a viable target 
for small molecule therapeutic intervention.5 Targeting the UPS 
upstream of the proteasome may therefore yield new opportu-
nities for targeted therapeutics with improved specificity and 
toxicity profiles.  
Ubiquitination is a post-translational modification via cova-
lent attachment of the 76 amino acid protein ubiquitin to lysine 
side chains of target substrates. This elegant and complex mo-
lecular “tagging” of target proteins is effected by E1 (activat-
ing), E2 (conjugating) and E3 (ligase) enzymes and has multi-
ple functions including targeted substrate degradation, activa-
tion for further processing and cellular localization.6 
The process of ubiquitination is reversed by deubiquitinase 
enzymes (DUBs) of which there are around 100 encoded by hu-
man genes.7 Ubiquitin specific proteases (USPs) are cysteine 
proteases that comprise the largest (>50) sub-class of DUBs and 
are gaining interest as an emerging target class for pharmaceu-
tical intervention.8 There are sparingly few validated small mol-
ecule inhibitors reported for USPs and as such there is an acute 
need to develop robust probe compounds for use in deciphering 
the biological pathways associated with the USP target class. 
USP7 represents one of the most studied USPs from a target 
class that remains largely underexplored and as such has gained 
attention in recent years due to its association with cancer.9,10 
USP7 is involved in the regulation of the stability of the tumor 
suppressor p53 via deubiquitination of the oncoprotein 
Mdm2.11 USP7 mediated stabilization of Mdm2 reduces cellu-
lar p53 and may protect damaged cells from apoptosis. In addi-
tion, USP7 has also been implicated in the regulation of several 
other key signaling proteins linked to tumorigenesis.12-17 Tar-
geting USP7 with small molecules has therefore been of great 
interest over recent years but has until recently met with limited 
success due to several factors including poor compound speci-
ficity, low potency and/or poor compound properties.18 Very re-
cent publications have described the characterization of more 
drug-like USP7 inhibitors that further reinforce the potential 
druggability of this target class.19-22 
Recently we published the detailed in vitro biological profil-
ing and co-crystal structures of highly potent non-covalent 
USP7 inhibitors in a variety of biochemical and cellular as-
says.22 These compounds have proven to be highly valuable 
tools for interrogating the complex biology of USP7 and will 
enable further studies aimed at delineating USP7 biology. 
Herein we describe the hit-finding and medicinal chemistry ef-
forts towards these tool compounds, summarize the SAR and 
outline the identification of a novel sub-series of USP7 inhibi-
tors. The binding mode (by way of X-ray co-crystallography) 
of this sub-series is highlighted as is the pharmacokinetic pro-
filing of early leads from both series.  
Our USP7 hit-finding strategy involved initial fragment 
screening using surface plasmon resonance (SPR) coupled with 
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the parallel in vitro benchmarking of published USP7 inhibi-
tors. Briefly, SPR screening of 1.9k fragments versus immobi-
lized USP7 catalytic domain afforded a range of primary USP7 
binding fragments including thieno-pyrimidinone 1 (Figure 1). 
N
NH
O
S
1
USP7 KD
 471 µM
LE = 0.47  
Figure 1. Primary USP7 SPR binding fragment 1. 
Compound 1 was found to be a high ligand efficiency USP7 
binder (LE = 0.47) with an SPR equilibrium binding constant 
(KD) of 471 µM (Figure S1, SI). Binding of compound 1 to 
USP7 was subsequently confirmed by orthogonal techniques 
(ligand observed STD, CPMG and WaterLOGSY NMR exper-
iments) (Figure S2, SI). Further profiling revealed that 1 had 
excellent aqueous kinetic solubility (>200 µM) and was free 
from redox cycling activity – a liability that has the potential to 
lead to false positive readouts in biochemical assays. 1 and an-
alogues thereof were then incorporated into our wider USP7 
medicinal chemistry program which involved scaffold-hopping 
as well as hybridization with known literature USP binding mo-
tifs (e.g. 4-hydroxypiperidines23). From this program of work 
compounds 2 and 3 were synthesized and found to have modest 
USP7 biochemical activity (Table 1). 
Table 1. Early USP7 hits and associated physicochemical 
properties. 
N
OH
R1
O  
Cmpd R1 
USP7 
IC50 
(µM) 
KSol 
(µM) LE MW/LogD7.4 
2 
N
N
O
S  
23 >200 0.23 397.5/1.9 
3 
N
N
O
S
 
78 186 0.21 397.5/1.7 
 
Compounds 2 and 3 were deemed suitable for further SAR 
studies due to their reasonable ligand efficiencies (LE) and fa-
vorable physicochemical properties. A range of analogues de-
rived by scaffold-hopping to other fused 5-membered ring py-
rimidinones were explored in parallel to substitution on the bi-
cyclic pyrimidinone core (Table 2). Furano, pyrazolo and thia-
zolo-pyrimidinone analogues 4-8 were largely equipotent with 
thieno-pyrimidinones 2 and 3. Substitution of a lipophilic bro-
mine atom at either the C-5 or C-6 positions of the thiophene 
ring in compounds 9 and 10 did not lead to marked USP7 po-
tency gains whereas substitution at the C-7 position led to an 
appreciable (ca. 5-fold) potency enhancement as demonstrated 
by compound 11. Pleasingly, substitution at this position with 
other lipophilic groups such as cyclopropyl 12, alkynyl 13 and 
phenyl 14 also afforded noticeable potency gains versus the 
non-substituted analogue 3. Substitution at the 2-position of the 
pyrimidinone ring with a methyl substituent was not tolerated 
(compound 15). 
Table 2. Early SAR of 5-membered heterocyclic pyrimidi-
nones. 
Cmpd R1 
USP7 
IC50 
(µM) 
Cmpd R1 
USP7 
IC50 
(µM)  
4 
N
N
O
O  
87 10 
N
N
O
S
Br
 
34 
5 
N
N
O
O
 
115 11 
N
N
O
S
Br  
13 
6 
N
N
O
N
N
 
44 12 N
N
O
S
 
20 
7 
N
N
O
N
N  
32 13 N
N
O
S
 
8 
8 
N
N
O
S
N
MeS
 
130 14 N
N
O
S
 
10 
9 
N
N
O
S
Br
 
60 15 
N
N
O
S
 
>200 
 
With potency gains of ca. 5-10 fold attainable via modifica-
tion of the bicyclic thienopyrimidinone ring, our attention 
turned to SAR analysis of the phenethylamide moiety. During 
the course of our studies a key breakthrough was the observa-
tion that methyl substitution at the benzylic position of com-
pounds such as 11 led to a significant (>40-fold) increase in 
USP7 potency. This large increase in potency was fully depend-
ent on the stereochemistry of the newly installed chiral methyl 
group as exemplified by compounds 16 and ent-16 (Figure 2).  
N
N
O
N
OH
O
S
ent-16 (S)-Me, USP7 IC50
 = 46.0 µM
Br
16 (R)-Me, USP7 IC50
 = 0.3 µM
 
Figure 2. Effects of benzylic substitution.  
Interestingly, the (R)-enantiomer 16 was found to be >150 
times more potent than the corresponding (S)-enantiomer ent-
16. With potent USP7 compounds such as 16 now in hand we 
initiated co-crystallization studies with the catalytic domain 
(amino acids 207-560) of USP7. We subsequently obtained a 
2.3 Å resolution X-ray co-crystal structure of compound 16 and 
USP7 that revealed the ligand bound in the catalytic cleft be-
tween the β-sheet of the palm subdomain and the helices of the 
thumb subdomain.22 Removal of key ligand hydrogen-bonding 
heteroatoms (such as the amide carbonyl, tertiary alcohol or py-
rimidinone N-1 nitrogen from the bicyclic core) was highly del-
eterious to USP7 binding (data not shown) highlighting the im-
portance of each individual interaction. 
Aided by the X-ray co-crystal structure, we were able to use 
structure-based design to further optimize our USP7 inhibitors 
with the aim of enhancing target affinity (whilst retaining fa-
vorable physicochemical properties). Our initial focus centered 
on the thiophene ring of compound 16 which contains a bro-
mine substituent at C-7 that is orientated towards the protein 
surface with a high degree of solvent exposure and was thus 
viewed as a promising vector for new analogue design and op-
timization. Encouragingly, scaffold-hopping from the thieno-
pyrimidinone core of compound 16 to the more drug-like N-
methyl pyrazolo-pyrimidine core (compound 17, Table 3) not 
only lowered overall lipohilicity (logD7.4 1.5 vs 2.3) but was 
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also not detrimental to USP7 activity. Given this result, we de-
cided to concentrate our efforts on the pyrazolo-pyrimidinone 
core and a summary of the SAR is presented in Table 3. 
Table 3. USP7 biochemical potencies of N-methyl pyra-
zolo-pyrimidinones. 
N
OH
N
O
N
O
N
N
R2  
 
Our strategy (guided by docking studies using the co-crystal 
structure) was centered on targeting both hydrogen-bond and 
hydrophobic interactions via selective substitution at the pyra-
zole C-3 position. Incorporation of alkynyl, alkenyl or isopro-
pyl substituents at the C-3 position (compounds 18-21) did not 
prove fruitful, however, when pyrazole or phenyl groups were 
incorporated at this position a ca. 10-fold increase in USP7 po-
tency was observed (e.g. compound 23, IC50 0.03 µM). This 
marked increase in potency may involve a CH-π interaction be-
tween the pendant pyrazole or phenyl groups of 22 or 23 and 
Gln351 as postulated in the published co-crystal structure.22 
Addition of an ortho-fluoro group to the pendant phenyl in 
compound 23 led to a slight decrease in potency (compound 24, 
IC50 0.09 µM) in contrast to ortho-anilino substituted com-
pound 25 which was around 40-fold less potent than 23 – pos-
sibly due to the larger ortho-NH2 substituent increasing the di-
hedral angle between the phenyl ring and the core, causing an 
unfavorable steric clash between the phenyl ring and the protein 
surface. Addition of hydrogen-bond acceptors and donors at the 
meta and para positions on the pendant phenyl group (com-
pounds 26-30) largely maintained potency in relation to 23 with 
the exception of compound 31 which showed a marked de-
crease in potency, most likely due to the added steric bulk of 
the morpholine group. Interestingly, the para-carboxamide or 
benzylic alcohol groups in compounds 32 and 33 did not lead 
to potency increases whereas the para-benzylic amine moiety 
in compound 34 (IC50 = 6 nM) provided a ca. 5-fold increase 
in potency over compound 23. The (S)-Me enantiomer of 34 
was found to have an IC50 of 2.4 µM, representing a 400-fold 
decrease in USP7 potency.22 
In addition to identifying the promising pyrazolo-pyrimidi-
nones described above, we also investigated how truncation of 
the bicyclic core would affect USP7 binding. Hence, a series of 
monocyclic pyrimidinones such as compound 35 were synthe-
sized (Table 4). Although only moderately active, compound 
35 (IC50 = 23 µM) represented a promising and ligand efficient 
(LE = 0.25) starting point for further analogue work with re-
spect to its low molecular weight and logD7.4 (355 and 0.9 re-
spectively). A range of analogues were subsequently prepared 
substituted at the C-6 position of the pyrimidinone ring with 
representative examples shown in Table 4.  
Table 4. USP7 biochemical potencies of monocyclic pyrim-
idinones. 
N
OH
N
O
Ph
N
O
R3
 
Cmpd R3 
USP7 
IC50 
(µM) 
Cmpd R3 
USP7 
IC50 
(µM) 
35 H  23 41 ON  7.2 
36 NH  4.2 42 N
N
 0.39 
37 N
H  
1.9 43 NH
O
 12 
38  
90 44 N
H
N
O
 
1.4 
39 
 
2.8 45 NHN  1.1 
40 N
H
N
 0.12 46 NH
N
 
0.09 
 
Overall SAR at this position suggested that substitution was 
largely beneficial for USP7 potency. Substitution with simple 
amines such as methylamine or aniline (compounds 36 and 37) 
increased potency by 5 to 10-fold versus the unsubstituted ana-
logue 35. Switching the –NH linker in compound 37 to –CH2 
in compound 38 resulted in a significant USP7 potency drop-
off (IC50 = 1.9 µM versus 90 µM). Potency was regained when 
the methylene phenyl linker in compound 38 was switched to 
an alkynyl linker group (compound 39, IC50 = 2.8 µM). Eth-
ylenediamine analogue 40 (IC50 = 0.12 µM) represented a 
>190-fold improvement in USP7 biochemical potency over the 
simple analogue 35 suggestive of new hydrogen-bonding inter-
actions. Indeed, close analogues of compound 40 in which the 
hydrogen-bonding interaction potential of the ethylenediamine 
side-chain was modified led to decreases in potency (com-
pounds 41-45). Pyrrolidine analogue 46 represented the first 
Cmpd R2 
USP7 
IC50 
(µM) 
Cmpd R2 
USP7 
IC50 
(µM)  
17 Br  0.3 26 
CN  
0.15 
18 
 
0.24 27 
NH2  
0.024 
19 
HO  
0.3 28 
OH  
0.039 
20 
 
0.33 29 
CONH2  
0.03 
21 
 
0.56 30 
NMe2  
0.075 
22 
N
NH
 
0.035 31 
N
O
 
0.25 
23 
 
0.03 32 
H2NOC  
0.05 
24 F
 
0.09 33 
OH  
0.04 
25 NH2
 
1.4 34 
NH2  
0.006 
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sub-100 nM compound from this series and suggested that the 
basic pyrrolidine nitrogen was making a critical hydrogen-bond 
with USP7. 
Intrigued by the observed SAR in which the precise nature of 
the side-chain linker and the pKa of the amine both seemed cru-
cial, molecular modelling suggested that a close interaction be-
tween the protonated amine of 46 and Asp295 was potentially 
achievable. This was subsequently confirmed via a high resolu-
tion (2.2 Å) X-ray co-crystal structure of compound 46 bound 
to USP7 that demonstrates a similar binding mode to that of 
compound 16 reported previously (Figures 3A and 3B).22 
 
 
Figure 3. A. High-resolution X-ray co-crystal structure of USP7 in 
complex with 46 (PDB code: 6F5H). B. Overlay of compounds 46 
(green) and 1622 (orange, PDB code: 5N9R) bound to USP7. 
In addition to the important hydrogen bond interaction net-
work observed previously with 16, we also observed the postu-
lated additional hydrogen bond between the protonated nitrogen 
of the pyrrolidine side-chain of 46 and Asp295 demonstrating a 
unique bidentate binding interaction pattern with Asp295 which 
had not been previously reported. This extra interaction appears 
to be crucial for improving affinity within the monocyclic se-
ries. As with compound 16, the amide carbonyl in 46 interacts 
with the Tyr465 hydroxyl group and the ligand tertiary alcohol 
and forms hydrogen bonds with both Asp295 and Val296. With 
regards to the pyrimidinone ring of 46, the carbonyl oxygen 
atom forms a hydrogen bond with the backbone NH of Phe409 
whereas the N-4 ring atom forms a hydrogen bond with Gln297 
effectively stabilizing the monocyclic ring with interactions 
above and below the ring system (Figure 3A). The folded bio-
active conformation of the phenethylamide side chain of 46 
may partly be induced by allylic 1,3-strain between the benzylic 
CH and the phenyl ring as well as stabilization via a CH-π in-
tramolecular interaction between the piperidine C-3 axial hy-
drogen and the phenyl ring. These intramolecular conforma-
tional drivers may in part be responsible for inducing binding 
site side-chain movements that create the overall binding 
pocket that accommodates this portion of the ligand. The result-
ing conformation is stabilized by a cation-π interaction between 
Lys420 and the ligand phenyl ring in addition to an edge-to-
face π-π interaction with Phe409. Additional contacts between 
the phenethylamide methylene hydrogen atoms of 46 and the π 
system of His461 may also contribute to overall binding effi-
ciency. 
With highly potent USP7 inhibitors (from two distinct sub-
series) such as 34 and 46 in hand, we performed extensive in 
vitro profiling and demonstrated that 34 shows potent target en-
gagement of endogenous USP7 in cells as well as excellent se-
lectivity for USP7 in panels of deubiquitinases, proteases and 
kinases.22 In addition, we also identified cancer cell lines that 
are hyper-sensitive to our USP7 inhibitors. Similar to com-
pound 34, monocyclic analogue 46 shows excellent selectivity 
versus a panel of USPs (n = 21) when screened at a fixed con-
centration of 10 µM as well as potent intracellular USP7 target 
engagement (EC50 = 0.32 µM) in cells (Figures 4A and 4B). 
 
 
Figure 4. A. Selectivity profile of 46 against a panel of 21 USPs. 
Screening was performed at a fixed concentration of 10 µM (Ubiq-
uigent). B. USP7 target engagement of 46 in HCT116 cells. See 
Supporting Information for assay conditions. 
In parallel to the in-depth cellular profiling outlined above, 
potent compounds were assessed in a range of in vitro assays in 
order to determine their suitability for in vivo studies. Gener-
ally, non-basic analogues were unstable in both human and 
mouse liver microsomes and had poor caco-2 permeability if 
they contained >1 hydrogen bond donor (HBD), thus preclud-
ing them from in vivo PK studies (e.g. compounds 23 and 33, 
Table 5). Likewise, benzylic amine 34 was found to have high 
in vitro metabolic turnover in both human and mouse liver mi-
crosomes (with predicted hepatic clearances of 18 mL/min/kg 
and 62 mL/min/kg respectively), whereas monocycle 46 had 
moderate metabolic stability in human and mouse liver micro-
somes (11 mL/min/kg and 34 mL/min/kg respectively). The 
aqueous kinetic solubility of both 34 and 46 was high (KSol > 
190 µM) but the caco-2 A:B permeability of each at pH 6.5 was 
found to be low (Papp < 0.3 x 10-6 cm/s) limiting their potential 
for oral dosing. The low predicted in vivo hepatic stability of 
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the highly potent benzylic amine 34 encouraged us to carry out 
further chemical optimization in order to identify compounds 
with improved metabolic stability to facilitate in vivo proof-of-
concept studies. As part of the chemistry program aimed at im-
proving metabolic stability of compound 34, trifluoromethyl 
analogue 47 (Figure S3, SI) was prepared via an asymmetric 
hydrogenation route described previously.22 
Table 5. Biochemical and ADME profiling of compounds 
23, 33, 34, 46 and 47. 
Cmpd 
USP7 
IC50 
(µM) 
HLM / 
MLM 
CLhep 
logD7.4 / 
KSol 
Caco-2 
Papp 
A:B 
23 0.030 19 / 84 2.3 / 175 1.93 
33 0.040 19 / 86 1.7 / 200 0.15 
34 0.006 18 / 62 -0.1 / 191 0.28 
46 0.087 11 / 34 0 / 200 0.26 
47 0.022 7 / 28 0.1 / 179 0.14 
Table notes: See Supporting Information for assay conditions. 
HLM/MLM units: mL/min/kg. KSol units: µM. Caco-2 units: 10-6 
cm/s 
Compound 47 was found to have improved in vitro microso-
mal stability in both human and mouse microsomes compared 
to compound 34 (HLM CLhep 7 mL/min/kg vs 18 mL/min/kg 
and MLM CLhep 28 mL/min/kg vs. 62 mL/min/kg) (Table 5). 
Furthermore, 47 largely maintained USP7 biochemical potency 
when contrasted with methyl analogue 34 (IC50 = 22 nM vs 6 
nM). 
The pharmacokinetic profiles of compounds 46 and 47 were 
subsequently assessed in male CD-1 mice (Table 6). As ex-
pected from their low caco-2 permeabilities (A:B Papp < 0.3 x 
10-6 cm/s) both compounds exhibited poor oral bioavailability 
(F < 1%). However, when dosed intraperitoneally (i.p.) both 
compounds exhibited reasonable bioavailability (F = 44% and 
64% for 46 and 47 respectively). Volume of distribution for 
each compound was low (Vss ≤ 1 L/kg), in line with their low 
lipophilicities (logD7.4 ≤ 0). Compound 46 demonstrated low 
plasma clearance (CL = 13 mL/min/kg) whereas compound 47 
had moderate clearance (CL = 32 mL/min/kg). Further optimi-
zation studies aimed at improving PK profiles based on these 
encouraging preliminary in vivo results are underway and will 
be reported in due course. 
Table 6. Pharmacokinetic profile of compounds 46 and 47 
in male CD-1 mice 
Routea Cmpd Cmaxb AUCallc t½d CLe Vss f 
i.v. 
46 4035 1700 1.1 13 0.4 
47 2808 516 1.0 32 0.9 
i.p 
46 3430 3002 1.1 - - 
47 2876 1904 0.8 - - 
a i.v. 46 1.3 mg/kg, 47 0.9mg/kg in 2% DMSO in 20% aq. 2-
hydroxypropyl-β-cyclodextrin, i.p. 46 6.2 mg/kg, 47 5.7 mg/kg in 
saline. b ng/mL. c ng.h/mL. d hr.  e mL/min/kg. f L/kg. 
In conclusion, we have identified and optimized highly po-
tent USP7 inhibitors based on two different core chemotypes. 
Key compounds have a well understood mode of binding as ev-
idenced by the high resolution co-crystal structures obtained. 
These USP7 inhibitors have been highly valuable in validating 
the druggability of USP7 as well as enabling studies towards a 
deeper understanding of the underlying biology of USP7 and its 
potential as a therapeutic target. Efforts are continuing towards 
the further development of these inhibitors into compounds 
suitable for in vivo proof-of-concept studies. 
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1. Materials and reagents: 
Common organic solvents that were used in reactions (e.g. THF, DMF, DCM, and methanol) were purchased anhy-
drous from Sigma-Aldrich® in Sure/SealTM bottles and were handled appropriately under nitrogen. Water was deionised 
using an Elga PURELAB Option-Q. All other solvents used (i.e. for work-up procedures and purification) were generally 
HPLC grade and were used as supplied from various commercial sources. Unless otherwise stated, all starting materials 
used were purchased from commercial suppliers and used as supplied. 
For assay purposes, all reagents and chemicals were purchased from Sigma-Aldrich® unless otherwise stated. All 
inhibitors were prepared as 10 mM DMSO stocks for cell culture experiments and stored in a controlled environment 
using the MultiPod system. CellTiter-Glo® was purchased from Promega (#G7571). The ubiquitin-propargylamine (Ub-
PA) probe was purchased from UbiQ (#UbiQ-057). Unless otherwise stated, all other reagents were obtained from com-
mercial sources and used without further purification. 
 
2. Experimental Procedures and Spectroscopic Data: 
 
Abbreviations and Acronyms 
aq: aqueous; Boc: tert-butyloxycarbonyl; DCM: dichloromethane; br: broad; d: doublet; DIPEA: diisopropylethyla-
mine; DMAP: 4-(dimethylamino)pyridine; DMF: N,N-dimethylformamide; DMSO: dimethylsulfoxide; dppf: 1,1′-
bis(diphenylphosphino)ferrocene; EDC: N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; EtOAc: ethyl 
acetate; ESI: electrospray ionisation; h: hour; HATU: N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide; HPLC: high pressure liquid chromatography; 
LC: liquid chromatography; LCMS: liquid chromatography mass spectrometry; m/z: mass-to-charge ratio; MeCN: ace-
tonitrile; MeOH: methanol; min: minutes; MS: mass spectrometry; m: multiplet (spectral); OAc: acetate; PE: petroleum 
ether (40-60 °C); RT: retention time; rt: room temperature; s: singlet; t: triplet; TFA: trifluoroacetic acid; THF: tetrahy-
drofuran.  
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General Experimental Conditions 
 
Microwave synthesis 
Microwave experiments were carried out using a Biotage Initiator™ Eight system or a CEM Discover™/Explorer24™ 
system controlled by Synergy 1.5 software. Both machines give good reproducibility and control at temperature ranges 
from 60-250 °C and pressures of up to a maximum of 20 bar. 
 
Flash chromatography 
Purification of compounds by flash chromatography was achieved using a Biotage Isolera Four system. Unless other-
wise stated, Biotage KP-Sil SNAP cartridge columns (10-340 g) were used along with the stated solvent system and an 
appropriate solvent gradient depending on compound polarity. In the case of more polar and basic compounds, Biotage 
KP-NH SNAP cartridge columns (11 g) were used. 
 
NMR spectroscopy 
1H NMR spectra were recorded at ambient temperature using a Bruker Avance (300 MHz), Bruker Avance III (400 
MHz) or Bruker Ascend (500 MHz) spectrometer. All chemical shifts (δ) are expressed in ppm. Residual solvent signals 
were used as an internal standard and the characteristic solvent peaks were corrected to the reference data outlined in J. 
Org. Chem., 1997, 62, p7512-7515; in other cases, NMR solvents contained tetramethylsilane, which was used as an 
internal standard. 
 
Liquid Chromatography Mass Spectrometry (LCMS)  
Liquid Chromatography Mass Spectrometry (LCMS) experiments to determine retention times (RT) and associated 
mass ions were performed using the following method: 
 
Method A: The system consisted of an Agilent Technologies 6130 quadrupole mass spectrometer linked to an Agilent 
Technologies 1290 Infinity LC system with UV diode array detector and autosampler. The spectrometer consisted of an 
electrospray ionization source operating in positive and negative ion mode. LCMS experiments were performed on each 
sample submitted using the following conditions: LC Column: Agilent Eclipse Plus C18 RRHD, 1.8 µm, 50 x 2.1 mm 
maintained at 40 °C. Mobile phases: A) 0.1% (v/v) formic acid in water; B) 0.1% (v/v) formic acid in acetonitrile. 
 
Gradient Time (min) Flow (mL/min) %A %B 
0.00 0.5 80 20 
1.80 0.5 0 100 
2.20 0.5 0 100 
2.50 0.5 80 20 
3.00 0.5 80 20 
 
 
Method B: The system consisted of an Agilent Technologies 6140 single quadrupole mass spectrometer linked to an 
Agilent Technologies 1290 Infinity LC system with UV diode array detector and autosampler. The spectrometer consisted 
of a multimode ionization source (electrospray and atmospheric pressure chemical ionizations) operating in positive and 
negative ion mode. LCMS experiments were performed on each sample submitted using the following conditions: LC 
Column: Zorbax Eclipse Plus C18 RRHD, 1.8 µm, 50 x 2.1 mm maintained at 40 °C. Mobile phases: A) 0.1% (v/v) 
formic acid in water; B) 0.1% (v/v) formic acid in acetonitrile. 
 
Gradient Time (min) Flow (mL/min) %A %B 
0.00 1.0 95 5 
1.80 1.0 0 100 
2.20 1.0 0 100 
2.21 1.0 95 5 
2.50 1.0 95 5 
 
 
Preparative High Pressure Liquid Chromatography  
Method A: This system consisted of an Agilent Technologies 6120 single quadrupole mass spectrometer linked to an 
Agilent Technologies 1200 Preparative LC system with multiple wavelength detector and autosampler. The mass spec-
trometer used a multimode ionization source (electrospray and atmospheric pressure chemical ionizations) operating in 
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positive and negative ion mode. Fraction collection was mass-triggered (multimode positive and negative ion). Purifica-
tion experiments, unless otherwise stated, were performed under basic conditions at an appropriate solvent gradient that 
was typically determined by the retention time found using the LCMS method. In cases where the basic conditions were 
unsuccessful, acidic conditions were employed. 
 
Basic conditions: LC Column: Waters XBridge™ Prep C18 5 μm OBDTM 19 x 50 mm column at rt. Mobile phase: 
A) 0.1% (v/v) ammonium hydroxide in water; B) 0.1% (v/v) ammonium hydroxide in 95:5, acetonitrile/water. Total 
experiment time was ca. 10 min and an example method is given: 
 
Gradient Time (min) Flow (mL/min) %A %B 
0.00 20.0 50 50 
3.00 20.0 12 88 
5.00 20.0 12 88 
7.00 20.0 0 100 
8.0 20.0 0 100 
8.20 20.0 50 50 
 
Acidic conditions: LC Column: Waters XBridge™ Prep C18 5μm OBDTM 19 x 50 mm column at rt. Mobile phase: 
A) Water 0.1% (v/v) formic acid in water; B) 0.1% (v/v) formic acid in 95:5, acetonitrile/water. Total experiment time 
was ca. 10 min and an example method is given: 
 
Gradient Time (min) Flow (mL/min) %A %B 
0.00 20.0 95 5 
7.00 20.0 0 100 
9.00 20.0 0 100 
9.20 20.0 95 5 
 
Method B: This system consisted of a Waters Autopurification HPLC/MS, with a Gemini NX-C18 column from Phe-
nomenex, 5 µm, 50 mm x 30 mm i.d., running at a flow rate of 60 mL/min, 25 °C with UV diode array detection (210–
400 nm) and mass-directed collection. A typical gradient was 5-50% HPLC grade acetonitrile (mobile phase B) in HPLC 
grade water + 0.1% (v/v) ammonia solution (mobile phase A) over 10 min, or modified as necessary. The mass spec-
trometer used was a Waters Micromass ZQ2000 spectrometer, operating in positive or negative ion electrospray ionisa-
tion modes, with a molecular weight scan range of 150 to 1000. 
 
The pure fractions were combined and concentrated using a Genevac EZ-2 Elite, unless stated otherwise. 
 
Final compound purity analysis 
The purity of final compounds was assessed by LCMS and 1H NMR. The HPLC purity of each compound was meas-
ured using the method stated compared to a blank. 
 
High Resolution Mass Spec 
High resolution mass spectra were acquired on a Thermo ScientificLTQ Orbitrap XL spectrometer at the EPSRC UK 
National Mass Spectrometry Facility (University of Swansea). 
 
General procedures 
 
General procedure 1: Epoxide opening with a pyrimidinone 
A suspension of the pyrimidinone (1 equiv.), epoxide (1-3 equiv.) and Cs2CO3 (1-3 equiv.) in DMF were heated at 80 
°C for 10-24 h. The reaction was allowed to cool to rt, saturated NH4Cl(aq) was added and the resulting mixture was 
extracted with DCM (x3) using a Biotage phase separator. The combined organic phases were concentrated under re-
duced pressure and the residue was purified by flash chromatography (Biotage KP-Sil and KP-NH, 0-100% EtOAc in 
cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product. 
 
General procedure 2: N-Boc deprotection 
A solution of the N-Boc piperidine in DCM/TFA was stirred for 1-24 h at rt before being concentrated under reduced 
pressure. The residue was then dissolved in triethylamine and DCM before being purified by flash chromatography 
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(Biotage KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc or 0-100% DCM in cyclohexane 
or PE, then 0-30% MeOH in DCM) to give the product. 
 
General procedure 3: EDC coupling 
A solution of amine (1 equiv.), carboxylic acid (1 equiv.) and EDC (3 equiv.) was stirred in (DCM) for 1-24 h at rt. 
The reaction was quenched by the addition of water and the resulting mixture was extracted with DCM (x3) using a 
Biotage phase separator. The combined organic phases were concentrated under reduced pressure and the residue was 
purified by flash chromatography (Biotage KP-Sil and KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH 
in EtOAc) to give the product. 
 
General procedure 4: HATU coupling in DCM 
To a suspension of the amine (1 equiv.), carboxylic acid (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DCM was added 
DIPEA (1-4 equiv.). The reaction was stirred for 1-24 h at rt before being quenched by the addition of saturated Na-
HCO3(aq) and the resulting mixture was extracted with DCM (x3) using a Biotage phase separator. The combined organic 
phases were concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil 
and KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product. 
 
General procedure 5: Suzuki-Miyaura coupling 
A reaction vial was charged with a mixture of the bromide (1 equiv.), the organoboron reagent (1-3 equiv.), a Pd catalyst 
(0.05-0.1 equiv.) and an inorganic base (2-5 equiv.) in 1,4-dioxane/water and the O2 was removed by evacuating and 
refilling with N2 three times or by bubbling N2 through the mixture before the reaction tube was sealed. The reaction 
was heated under the indicated conditions for the indicated time before being cooled to rt and saturated NH4Cl(aq) added. 
The resulting mixture was extracted with DCM (x3) using a Biotage phase separator. The combined organic phases were 
concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil and/or KP-
NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to give the product. 
 
General procedure 6: Sonagashira coupling 
A reaction tube was charged with the bromide (1 equiv.), a Cu catalyst (0.2-0.4 equiv.) and a Pd catalyst (0.1-0.2 equiv.) 
and then evacuated and refilled with N2 three times. To this was added toluene, triethylamine (20-40 equiv.) and the 
alkyne (1-4 equiv.) before the mixture was again evacuated and refilled with N2 three times. The reaction tube was sealed 
and the reaction was heated under the indicated conditions for the indicated time. The reaction was cooled to rt and 
quenched by the addition of saturated NH4Cl(aq). The mixture was extracted with DCM (x 3) using a Biotage phase 
separator, the combined organic phases were concentrated under reduced pressure and the residue was purified by flash 
chromatography (Biotage KP-Sil and KP-NH, 0-100% EtOAc in cyclohexane or PE, then 0-30% MeOH in EtOAc) to 
give the product. 
 
Compounds 11, 16, ent-16, 17, 34, ent-34 and 47 were prepared as described previously.1 
 
Compound 2: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[2,3-d]pyrimidin-4(3H)-one 
N
N
S
O
N
OH
O  
General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (63 mg, 0.257 mmol), 
thieno[2,3-d]pyrimidin-4(3H)-one (36 mg, 0.237 mmol), Cs2CO3 (91 mg, 0.279 mmol) and DMF (1.5 ml) gave title 
compound (48 mg, 51%) as a colourless solid. LCMS (Method A, ES+): RT = 1.08 min (purity >97% at 254 nm), m/z 
Calcd for C21H24N3O3S [M+H]+ 398, found 398. ¹H NMR (400 MHz, CDCl3): δ 8.07 (s, 1H), 7.45 (d, 1H), 7.34-7.23 
(m, 3H), 7.22-7.11 (m, 3H), 4.32 (d, 1H), 4.09 (d, 1H), 3.98 (d, 1H), 3.58 (d, 1H), 3.42-3.21 (m, 1H), 3.10-2.98 (m, 1H), 
2.96-2.84 (m, 2H), 2.69-2.49 (m, 2H), 1.68-1.29 (m, 4H). 
 
Compound 3: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-one 
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N
NS
O
N
OH
O  
Step 1: tert-Butyl 4-hydroxy-4-((4-oxothieno[3,2-d]pyrimidin-3(4H)-yl)methyl)piperidine-1-carboxylate: Gen-
eral procedure 1 using tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate1 (640 mg, 3.00 mmol), thieno[3,2-d]pyrim-
idin-4(3H)-one (502 mg, 3.30 mmol), Cs2CO3 (977 mg, 3.00 mmol) and DMF (6 mL) gave the title compound (889 mg, 
81%) as a pale yellow foam. LCMS (Method A, ES+): RT = 1.07 min, m/z Calcd for C17H24N3O4S [M+H]+ 366, found 
366. ¹H NMR (300 MHz, CDCl3): δ 8.18 (s, 1H), 7.70 (d, 1H), 7.18 (d, 1H), 4.25-3.87 (m, 2H), 3.76 (br s, 2H), 3.08 (t, 
2H), 1.67-1.39 (m, 4H), 1.33 (s, 9H). 
 
Step 2: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-one: A solu-
tion of tert-butyl 4-hydroxy-4-((4-oxothieno[3,2-d]pyrimidin-3(4H)-yl)methyl)piperidine-1-carboxylate (15 mg, 41.0 
µmol) was stirred in TFA (1 mL) for 16 h at rt. The resulting mixture was concentrated under reduced pressure and to 
the residue were successively added DCM (0.33 mL), DIPEA (13.8 μL), 3-phenylpropanoic acid (4.75 mg, 0.032 mmol), 
EDC (10.1 mg, 0.053 mmol), and HOBt (8 mg, 0.053 mmol). The reaction mixture was stirred for 30 min at rt before 
being diluted with water (10 mL) and the resulting mixture was extracted with DCM (3 x 10 mL) using a Biotage phase 
separator. The combined organic phases were concentrated under reduced pressure and the residue was purified by flash 
chromatography (Biotage KP-Sil 10 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title 
compound (4 mg, 24%) as a colourless solid. LCMS (Method A, ES+): RT = 1.00 min (purity >95% at 254 nm), m/z 
Calcd for C21H24N3O3S [M+H]+ 398, found 398. ¹H NMR (300 MHz, CDCl3): δ 8.05 (s, 1H), 7.84 (d, 1H), 7.35 (d, 
1H), 7.32-7.19 (m, 5H), 4.41 (d, 1H), 4.13-4.00 (m, 2H), 3.62 (s, 1H), 3.60 (d, 1H), 3.33 (t, 1H), 3.08-2.94 (m, 3H), 2.66-
2.59 (m, 2H), 1.69-1.25 (m, 4H). 
 
Compound 4: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)furo[2,3-d]pyrimidin-4(3H)-one 
N
N
O
O
N
OH
O  
Step 1: tert-Butyl 4-hydroxy-4-((2-iodofuran-3-carboxamido)methyl)piperidine-1-carboxylate: General proce-
dure 3 using tert-butyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate (100 mg, 0.434 mmol), 2-iodofuran-3-car-
boxylic acid (103 mg, 0.434 mmol), EDC (166 mg, 0.868 mmol) and DCM (5.4 mL) gave the title compound (123 mg, 
62%) as a yellow solid. LCMS (Method A, ES+): RT = 1.22 min, m/z Calcd for C16H23IN2NaO5 [M+Na]+ 473, found 
473. 
 
Step 2: tert-Butyl 4-hydroxy-4-((4-oxofuro[2,3-d]pyrimidin-3(4H)-yl)methyl)piperidine-1-carboxylate: A sus-
pension of tert-butyl 4-hydroxy-4-((2-iodofuran-3-carboxamido)methyl)piperidine-1-carboxylate (400 mg, 0.888 
mmol), formamidine hydrochloride (358 mg, 4.44 mmol), CuI (17 mg, 89.2 µmol) and K2CO3 (368 mg, 2.67 mmol) in 
DMF (6 mL) was heated in a microwave at 150 °C for 8 h. The reaction mixture was partitioned between 1:1 brine/water 
(40 mL) and EtOAc (10 mL) and the mixture was filtered through a plug of Celite®. The aqueous layer was separated 
and extracted into EtOAc (3 x 10 mL). The combined organic layers were washed with 1:1 brine/water (40 mL), dried 
over Na2SO4, concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-
Sil 50 g cartridge, 0-100% EtOAc in PE) to give the title compound (34 mg, 10%) as a pale yellow solid. LCMS (Method 
A, ES+): RT = 1.17 min, m/z Calcd for C17H23N3NaO5 [M+Na]+ 372, found 372. 
 
Step 3: 3-((4-Hydroxypiperidin-4-yl)methyl)furo[2,3-d]pyrimidin-4(3H)-one: General procedure 2 using tert-bu-
tyl 4-hydroxy-4-((4-oxofuro[2,3-d]pyrimidin-3(4H)-yl)methyl)piperidine-1-carboxylate (34 mg, 97.3 µmol), TFA (0.6 
mL) and DCM (0.6 mL) gave the title compound (23 mg, 94%) as a pale yellow solid. LCMS (Method A, ES+): RT = 
0.23 min, m/z Calcd for C12H16N3O3 [M+H]+ 250, found 250. 
 
Step 4: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)furo[2,3-d]pyrimidin-4(3H)-one: General 
procedure 3 using 3-((4-hydroxypiperidin-4-yl)methyl)furo[2,3-d]pyrimidin-4(3H)-one (23 mg, 92.3 µmol), 3-phe-
nylpropanoic acid (14 mg, 92.3 µmol), EDC (53 mg, 0.277 mmol) and DCM (0.9 mL) gave the title compound (13 mg, 
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36%) as a colourless solid. LCMS (Method A, ES+): RT = 0.91 min (purity >95% at 254 nm), m/z Calcd for C21H24N3O4 
[M+H]+ 382, found 382. ¹H NMR (300 MHz, CDCl3): δ 7.99 (s, 1H), 7.49 (d, 1H), 7.33-7.21 (m, 5H), 6.92 (d, 1H), 4.41 
(d, 1H), 4.16-4.00 (m, 2H), 3.56 (d, 1H), 3.32 (t, 1H), 3.08-2.94 (m, 4H), 2.66-2.60 (m, 2H), 1.65-1.27 (m, 4H). 
 
Compound 5: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)furo[3,2-d]pyrimidin-4(3H)-one 
N
NO
O
N
OH
O  
General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (81 mg, 0.331 mmol), 
furo[3,2-d]pyrimidin-4(3H)-one (45 mg, 0.331 mmol), Cs2CO3 (323 mg, 0.992 mmol) and DMF (0.6 mL) gave the title 
compound (100 mg, 79%) as a colourless solid. LCMS (Method A, ES+): RT = 0.94 min (purity >98% at 254 nm), m/z 
Calcd for C21H24N3O4 [M+H]+ 382, found 382. ¹H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H), 7.81 (d, 1H), 7.32-7.19 (m, 
5H), 6.80 (d, 1H), 4.35 (d, 1H), 4.17-4.00 (m, 2H), 3.92 (s, 1H), 3.60 (d, 1H), 3.33 (t, 1H), 3.09-2.92 (m, 3H), 2.65-2.58 
(m, 2H), 1.61-1.26 (m, 4H). 
 
Compound 6: 6-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyra-
zolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O  
General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (65 mg, 0.266 mmol), 2-me-
thyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Oslob, J. D.; Yu, C. H. WO 2007/013964 A1; Feb 01, 2007) (40 
mg, 0.266 mmol) and Cs2CO3 (260 mg, 0.799 mmol) gave the title compound (54 mg, 51%) as a colourless solid. LCMS 
(Method A, ES+): RT = 0.85 min (purity >96% at 254 nm), m/z Calcd for C21H26N5O3 [M+H]+ 396, found 396. ¹H NMR 
(300 MHz, CDCl3): δ 7.91 (s, 1H), 7.78 (s, 1H), 7.31-7.18 (m, 5H), 4.32 (d, 1H), 4.21-3.95 (m, 5H), 3.60 (d, 1H), 3.38-
3.30 (m, 1H), 3.10-3.01 (m, 1H), 2.92 (t, 2H), 2.66-2.55 (m, 2H), 1.62-1.37 (m, 4H). 
 
Compound 7: 5-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-1-methyl-1,5-dihydro-4H-pyra-
zolo[3,4-d]pyrimidin-4-one 
N
N
N
N
O
N
OH
O  
General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (48 mg, 0.196 mmol), 1-me-
thyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (27 mg, 0.180 mmol), Cs2CO3 (70 mg, 0.213 mmol) and DMF 
(1.5 mL) gave the title compound (43 mg, 60%) as a colourless solid. LCMS (Method A, ES+): RT = 0.93 min (purity 
>98% at 254 nm), m/z Calcd for C21H26N5O3 [M+H]+ 396, found 396. ¹H NMR (300 MHz, CDCl3): δ 8.05 (s, 1H), 8.03 
(s, 1H), 7.36-7.24 (m, 2H), 7.24-7.10 (m, 3H), 4.31 (d, 1H), 4.13-4.07 (m, 1H), 3.97 (s, 3H), 3.96-3.88 (m, 1H), 3.58 (d, 
1H), 3.41-3.21 (m, 1H), 3.12-2.97 (m, 1H), 2.97-2.84 (m, 2H), 2.71-2.48 (m, 2H), 1.65-1.29 (m, 4H). 
 
Compound 8: 6-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-2-(methylthio)thiazolo[4,5-d]py-
rimidin-7(6H)-one 
N
NS
N
O
N
OH
O
MeS
 
General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (55 mg, 0.224 mmol), 2-(me-
thylthio)thiazolo[4,5-d]pyrimidin-7(6H)-one (Prepared according to Liebigs Annalen der Chemie, 1989, p409-411) (41 
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mg, 0.206 mmol), Cs2CO3 (80 mg, 0.246 mmol) and DMF (1.5 mL) gave the title compound (36 mg, 39%) as a colour-
less solid. LCMS (Method A, ES+): RT = 1.12 min (purity >99% at 254 nm), m/z Calcd for C21H25N4O3S2 [M+H]+ 445, 
found 445. ¹H NMR (300 MHz, CDCl3): δ 8.20 (s, 1H), 7.47-7.06 (m, 5H), 4.69-4.28 (m, 2H), 4.17-3.90 (m, 2H), 3.62 
(d, 1H), 3.49-3.26 (m, 1H), 3.19-2.87 (m, 3H), 2.74 (s, 3H), 2.69-2.50 (m, 2H), 1.87-1.32 (m, 4H). 
 
Compound 9: 6-Bromo-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-
4(3H)-one 
N
NS
O
N
OH
O
Br
 
Step 1: 6-Bromothieno[3,2-d]pyrimidin-4(3H)-one: To a solution of 6-bromo-4-chlorothieno[3,2-d]pyrimidine (600 
mg, 2.40 mmol) in THF (5 mL) was added 1 M NaOH(aq) (3.61 mL, 3.61 mmol). The reaction was stirred at rt for 17 h 
before the reaction was heated to 50 °C for 3 h. The reaction was cooled to rt and 1 M HCl(aq) was added until a neutral 
pH was achieved. The product was collected by filtration and subsequently three additional batches of the product were 
collected from the mother liquor after allowing it to stand for ~1 h. All the batches were dried in vacuo to give the title 
compound (471 mg, 84%) as a yellow solid. LCMS (Method A, ES+): RT = 0.75 min, m/z Calcd for C6H4BrN2OS 
[M+H]+  231, 233, found 231, 233. ¹H NMR (300 MHz, DMSO-d6): δ 8.15 (s, 1H), 7.61 (s, 1H). 
 
Step 2: 6-Bromo-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-
one: General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (45 mg, 0.183 mmol), 6-
bromothieno[3,2-d]pyrimidin-4(3H)-one (39 mg, 0.169 mmol), Cs2CO3 (65 mg, 0.199 mmol) and DMF (1.5 mL) gave, 
after purification by preparative HPLC, the title compound (4.2 mg, 5%) as a colourless solid. LCMS (Method A, ES+): 
RT = 1.29 min (purity >98% at 254 nm), m/z Calcd for C21H23BrN3O3S [M+H]+ 476, 478, found 476, 478. ¹H NMR 
(300 MHz, CDCl3): δ 8.03 (s, 1H), 7.45-7.15 (m, 6H), 4.40 (d, 1H), 4.04 (dd, 2H), 3.61 (d, 1H), 3.44-3.19 (m, 1H), 3.14-
2.90 (m, 4H), 2.78-2.51 (m, 2H), 1.65-1.39 (m, 2H), 1.39-1.14 (m, 2H). 
 
Compound 10: 5-Bromo-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[2,3-d]pyrimidin-
4(3H)-one  
N
N
S
O
N
OH
O
Br
 
Step 1: 5-Bromothieno[2,3-d]pyrimidin-4(3H)-one: To a stirred suspension of thieno[2,3-d]pyrimidin-4(3H)-one 
(250 mg, 1.64 mmol) in acetic acid (1.6 mL) in a reaction tube was dropwise added Br2 (0.254 mL, 4.93 mmol). The 
reaction tube was sealed and the mixture was heated at 95 °C for 16 h before the reaction was allowed to cool to rt. To 
this mixture was added MeOH (7 mL) and Et2O (7 mL). The resulting precipitate was collected by filtration and washed 
with Et2O (50 mL) before being dried under high vacuum to give the title compound (352 mg, 93%) as a beige solid. 
LCMS (Method A, ES+): RT = 0.84 min, m/z Calcd for C6H4BrN2OS [M+H]+ 231, 233, found 231, 233. ¹H NMR (300 
MHz, DMSO-d6): δ 12.67 (br s, 1H), 8.15 (s, 1H), 7.55 (s, 1H). 
 
Step 2: 5-Bromo-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[2,3-d]pyrimidin-4(3H)-
one: General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (49 mg, 0.200 mmol), 5-
bromothieno[2,3-d]pyrimidin-4(3H)-one (42 mg, 0.182 mmol), Cs2CO3 (71 mg, 0.218 mmol) in DMF (1.5 ml) gave the 
title compound (26 mg, 30%) as a colourless solid. LCMS (Method A, ES+): RT = 1.34 min (purity >96% at 254 nm), 
m/z Calcd for C21H23BrN3O3S [M+H]+ 476, 478, found 476, 478. ¹H NMR (300 MHz, CDCl3): δ 8.00 (s, 1H), 7.48 (s, 
1H), 7.42-7.14 (m, 5H), 4.36 (d, 1H), 4.11 (d, 1H), 3.97 (d, 1H), 3.73-3.54 (m, 2H), 3.46-3.21 (m, 1H), 3.18-2.87 (m, 
3H), 2.79-2.49 (m, 2H), 1.69-1.30 (m, 4H). 
 
Compound 12: 7-Cyclopropyl-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrim-
idin-4(3H)-one 
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N
NS
O
N
OH
O
 
General procedure 5 using 7-bromo-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrim-
idin-4(3H)-one1 (23 mg, 48.3 µmol), cyclopropylboronic acid (12 mg, 0.145 mmol), PdCl2(dppf) (3.5 mg, 4.83 µmol) 
and K3PO4 (46 mg, 0.217 mmol) in 1,4-dioxane (0.5 mL) and water (0.1 mL) at 110 °C for 16 h gave the title compound 
(9.5 mg, 44%) as a colourless solid. LCMS (Method A, ES+): RT = 1.29 min (purity >98% at 254 nm), m/z Calcd for 
C24H28N3O3S [M+H]+ 438, found 438. ¹H NMR (300 MHz, CDCl3): δ 8.07 (s, 1H), 7.40-7.14 (m, 6H), 4.43 (d, 1H), 
4.18-4.06 (m, 2H), 3.75-3.48 (m, 1H), 3.44-3.24 (m, 1H), 3.14-2.89 (m, 3H), 2.72-2.53 (m, 2H), 2.33-2.14 (m, 1H), 1.70-
1.30 (m, 5H), 1.12-0.92 (m, 2H), 0.92-0.70 (m, 2H). 
 
Compound 13: 7-Ethynyl-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-
4(3H)-one 
N
NS
O
N
OH
O
 
Step 1: tert-Butyl 4-hydroxy-4-((4-oxo-7-((trimethylsilyl)ethynyl)thieno[3,2-d]pyrimidin-3(4H)-yl)methyl)pi-
peridine-1-carboxylate: General procedure 6 using tert-butyl 4-((7-bromo-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl)me-
thyl)-4-hydroxypiperidine-1-carboxylate1 (102 mg, 0.230 mmol), CuI (8.7 mg, 45.7 µmol), Pd(PPh3)2Cl2 (16 mg, 22.8 
µmol), triethylamine (0.640 mL, 4.59 mmol), ethynyltrimethylsilane (0.127 mL, 0.917 mmol) and toluene (2 mL) at 110 
°C for 16 h gave the title compound (100 mg, 94%) as a yellow oil. LCMS (Method A, ES+): RT = 1.76 min, m/z Calcd 
for C22H32N3O4SSi [M+H]+ 462, found 462. ¹H NMR (400 MHz, CDCl3): δ 8.21 (s, 1H), 7.96 (s, 1H), 4.27-4.03 (m, 
2H), 3.97-3.75 (m, 2H), 3.15 (t, 2H), 3.06 (s, 1H), 1.78-1.49 (m, 4H), 1.45 (s, 9H), 0.29 (s, 9H). 
 
Step 2: 7-Ethynyl-3-((4-hydroxypiperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-one: General procedure 2 
using tert-butyl 4-hydroxy-4-((4-oxo-7-((trimethylsilyl)ethynyl)thieno[3,2-d]pyrimidin-3(4H)-yl)methyl)piperidine-1-
carboxylate (112 mg, 0.243 mmol), TFA (2 mL) and DCM (2 mL) gave a mixture of the TMS and desilated alkyne. This 
material was treated with K2CO3 (101 mg, 0.731 mmol) in MeOH for 45 min before the reaction mixture was purified 
directly by flash chromatography (Biotage KP-NH 11 g cartridge, 0-100% DCM in PE, then 0-40% MeOH in DCM) to 
give the title compound (51 mg, 72%) as a colourless solid. LCMS (Method A, ES+): RT = 0.23 min, m/z Calcd for 
C14H16N3O2S [M+H]+ 290, found 290. ¹H NMR (400 MHz, CDCl3): δ 8.27 (s, 1H), 7.98 (s, 1H), 4.14 (s, 2H), 3.41 (s, 
1H), 3.01-2.84 (m, 4H), 1.91-1.44 (m, 6H). 
 
Step 3: 7-Ethynyl-3-((4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-
one: General procedure 4 using 7-ethynyl-3-((4-hydroxypiperidin-4-yl)methyl)thieno[3,2-d]pyrimidin-4(3H)-one (18 
mg, 62.2 µmol), 3-phenylpropanoic acid (14 mg, 93.3 µmol), HATU (35 mg, 93.3 µmol), DIPEA (42 μL, 0.243 mmol) 
and DCM (0.5 mL) gave the title compound (24 mg, 91%) as a colourless solid. LCMS (Method A, ES+): RT = 1.15 min 
(purity >95% at 254 nm), m/z Calcd for C23H24N3O3S [M+H]+ 422, found 422. ¹H NMR (400 MHz, CDCl3): δ 8.19 (s, 
1H), 7.99 (s, 1H), 7.33-7.25 (m, 2H), 7.24-7.16 (m, 3H), 4.34 (d, 1H), 4.12 (d, 1H), 4.02 (d, 1H), 3.59 (d, 1H), 3.52 (s, 
1H), 3.41-3.25 (m, 2H), 3.11-2.99 (m, 1H), 2.99-2.89 (m, 2H), 2.70-2.52 (m, 2H), 1.67-1.28 (m, 4H). 
 
Compound 14: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-7-phenylthieno[3,2-d]pyrimidin-
4(3H)-one 
N
NS
O
N
OH
O
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Step 1: tert-Butyl 4-hydroxy-4-((4-oxo-7-phenylthieno[3,2-d]pyrimidin-3(4H)-yl)methyl)piperidine-1-carbox-
ylate: General procedure 5 using tert-butyl 4-((7-bromo-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl)methyl)-4-hydroxypi-
peridine-1-carboxylate1 (50 mg, 0.113 mmol), phenylboronic acid (41 mg, 0.338 mmol), PdCl2(dppf) (8.2 mg, 11.2 
µmol) and K3PO4 (108 mg, 0.506 mmol) in 1,4-dioxane (1 mL) and water (0.2 mL) at 110 °C for 16 h gave the title 
compound (48 mg, 96%) as a beige solid. LCMS (Method A, ES+): RT = 1.59 min, m/z Calcd for C23H28N3O4S [M+H]+ 
442, found 442. ¹H NMR (300 MHz, CDCl3): δ 8.17 (s, 1H), 7.87 (s, 1H), 7.82-7.72 (m, 2H), 7.54-7.34 (m, 3H), 4.28-
3.99 (m, 2H), 3.89 (br s, 2H), 3.41 (s, 1H), 3.15 (t, 2H), 1.72-1.48 (m, 4H), 1.45 (s, 9H). 
 
Step 2: 3-((4-Hydroxypiperidin-4-yl)methyl)-7-phenylthieno[3,2-d]pyrimidin-4(3H)-one: General procedure 2 
using tert-butyl 4-hydroxy-4-((4-oxo-7-phenylthieno[3,2-d]pyrimidin-3(4H)-yl)methyl)piperidine-1-carboxylate (48 
mg, 0.109 mmol), TFA (1 mL) and DCM (1 mL) gave the title compound (30 mg, 80%) as a colourless solid. LCMS 
(Method A, ES+): RT = 0.73 min, m/z Calcd for C18H20N3O2S [M+H]+ 342, found 342. ¹H NMR (300 MHz, CDCl3): δ 
8.21 (s, 1H), 7.85 (s, 1H), 7.83-7.73 (m, 2H), 7.65-7.32 (m, 3H), 4.12 (s, 2H), 3.12-2.74 (m, 4H), 2.19 (br s, 2H), 1.83-
1.47 (m, 4H). 
 
Step 3: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-7-phenylthieno[3,2-d]pyrimidin-4(3H)-
one: General procedure 4 using 3-((4-hydroxypiperidin-4-yl)methyl)-7-phenylthieno[3,2-d]pyrimidin-4(3H)-one (30 
mg, 87.9 µmol), 3-phenylpropanoic acid (20 mg, 0.132 mmol), HATU (50 mg, 0.132 mmol), DIPEA (61 μL, 0.351 
mmol) and DCM (1 mL) gave the title compound (22 mg, 52%) as a colourless solid. LCMS (Method A, ES+): RT = 
1.47 min (purity >97% at 254 nm), m/z Calcd for C27H28N3O3S [M+H]+ 474, found 474. ¹H NMR (300 MHz, CDCl3): 
δ 8.09 (s, 1H), 7.91 (s, 1H), 7.87-7.76 (m, 2H), 7.59-7.45 (m, 2H), 7.44-7.37 (m, 1H), 7.35-7.16 (m, 5H), 4.44 (d, 1H), 
4.14 (d, 1H), 4.05 (d, 1H), 3.63 (d, 1H), 3.45 (br s, 1H), 3.42-3.24 (m, 1H), 3.18-2.88 (m, 3H), 2.76-2.55 (m, 2H), 1.77-
1.34 (m, 4H). 
 
Compound 15: 3-((4-Hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl)methyl)-2-methylthieno[3,2-d]pyrimidin-
4(3H)-one 
N
NS
O
N
OH
O  
General procedure 1 using 3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)propan-1-one1 (70 mg, 0.285 mmol), 2-me-
thylthieno[3,2-d]pyrimidin-4(3H)-one (43 mg, 0.259 mmol), Cs2CO3 (101 mg, 0.311 mmol) in DMF (1.5 ml) gave the 
title compound (29 mg, 27%) as a pale yellow solid. LCMS (Method A, ES+): RT = 1.08 min (purity >98% at 254 nm), 
m/z Calcd for C22H26N3O3S [M+H]+ 412, found 412. 1H NMR (300 MHz, CDCl3): δ 7.82-7.66 (m, 1H), 7.29-7.08 (m, 
6H), 4.45-4.34 (m, 1H), 4.26 (br s, 1H), 4.19 (d, 1H), 4.07 (d, 1H), 3.59-3.47 (m, 1H), 3.34-3.18 (m, 1H), 2.95-2.80 (m, 
3H), 2.60 (s, 3H), 2.58-2.44 (m, 2H), 1.61-1.21 (m, 4H). 
 
Compound 18: (R)-3-Ethynyl-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihy-
dro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
 
Step 1: tert-Butyl 4-hydroxy-4-((2-methyl-7-oxo-3-((trimethylsilyl)ethynyl)-2,7-dihydro-6H-pyrazolo[4,3-d]py-
rimidin-6-yl)methyl)piperidine-1-carboxylate: General procedure 6 using tert-butyl 4-((3-bromo-2-methyl-7-oxo-2,7-
dihydro-6H-pyrazolo[4,3-d]pyrimidin-6-yl)methyl)-4-hydroxypiperidine-1-carboxylate1 (60 mg, 0.136 mmol), CuI (5.2 
mg, 27.3 µmol), Pd(PPh3)2Cl2 (9.5 mg, 13.5 µmol), triethylamine (0.378 mL, 2.71 mmol), ethynyltrimethylsilane (75 
μL, 0.918 mmol) and toluene (1.4 mL) at 110 °C for 16 h gave the title compound (41 mg, 65%) as a yellow oil. LCMS 
(Method A, ES+): RT = 1.60 min, m/z Calcd for C22H34N5O4Si [M+H]+ 460, found 460. ¹H NMR (300 MHz, CDCl3): δ 
7.94 (s, 1H), 4.27-4.00 (m, 5H), 4.00-3.77 (m, 2H), 3.27-3.06 (m, 3H), 1.75-1.39 (m, 13H), 0.31 (s, 9H). 
 
Step 2: 3-Ethynyl-6-((4-hydroxypiperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-
one: General procedure 2 using tert-butyl 4-hydroxy-4-((2-methyl-7-oxo-3-((trimethylsilyl)ethynyl)-2,7-dihydro-6H-
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pyrazolo[4,3-d]pyrimidin-6-yl)methyl)piperidine-1-carboxylate (32 mg, 69.6 µmol), TFA (1 mL) and DCM (1 mL) gave 
a mixture of the TMS and desilated alkyne. This material was treated with K2CO3 (29 mg, 0.209 mmol) in MeOH (1 
mL) for 45 min before the reaction mixture was purified directly by flash chromatography (Biotage KP-NH 11 g car-
tridge, 0-100% DCM in PE then 0-40% MeOH in DCM) affording the title compound (16 mg, 79%) as a colourless 
solid. LCMS (Method A, ES+): RT = 0.33 min, m/z Calcd for C14H18N5O2 [M+H]+ 288, found 288. 
 
Step 3: (R)-3-Ethynyl-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-py-
razolo[4,3-d]pyrimidin-7-one: General procedure 3 using 3-ethynyl-6-((4-hydroxypiperidin-4-yl)methyl)-2-methyl-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (12 mg, 41.8 µmol), (R)-3-phenylbutanoic acid (7 mg, 41.8 µmol), 
EDC (24 mg, 0.125 mmol) and DCM (0.4 mL) gave the title compound (9 mg, 49%) as a colourless solid. LCMS 
(Method A, ES+): RT = 1.06 min (purity >99% at 254 nm), m/z Calcd for C24H28N5O3 [M+H]+ 434, found 434. ¹H NMR 
(300 MHz, CDCl3, this molecule appears conformers in a 2:3 ratio): δ 7.94 (s, 0.4H), 7.82 (s, 0.6H), 7.39-7.16 (m, 5H), 
4.42-4.32 (m, 1H), 4.17 (s, 3H), 4.01-3.88 (m, 2H), 3.61-2.87 (m, 5H), 2.71-2.41 (m, 2H), 1.67-1.23 (m, 7.4H), 0.89-
0.75 (m, 0.6). 
 
Compound 19: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-3-(3-hydroxy-3-methylbut-1-
yn-1-yl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
OH  
General procedure 6 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (40 mg, 81.9 µmol), CuBr·SMe2 (0.7 mg, 3.28 μmol), Pd(PPh3)4 (1.9 mg, 
1.64 μmol), triethylamine (0.46 mL, 3.28 mmol) and 2-methylbut-3-yn-2-ol (8 mg, 98.3 µmol) at 70 °C for 1 h gave the 
title compound (27 mg, 67%) as a colourless solid. LCMS (Method A, ES+): RT = 1.06 min (purity >99% at 254 nm), 
m/z Calcd for C27H34N5O4 [M+H]+ 492, found 492. ¹H NMR (300 MHz, CDCl3, this molecule appears as conformers 
in a 2:3 ratio): δ 7.94 (s, 0.4H), 7.86 (s, 0.6H), 7.37-7.15 (m, 5H), 4.45-3.83 (m, 6H), 3.63-3.46 (m, 1H), 3.39-3.19 (m, 
2H), 3.12-2.90 (m, 1H), 2.71-2.41 (m, 2H), 2.08 (br s, 2H), 1.76-1.21 (m, 12.4H), 1.01-0.82 (m, 0.6H). 
 
Compound 20: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-(prop-1-en-2-yl)-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
 
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (75 mg, 0.154 mmol), potassium isopropenyltrifluoroborate (68 mg, 0.461 
mmol), K3PO4 (98 mg, 0.461 mmol), Pd(PPh3)4 (18 mg, 15.4 µmol), 1,4-dioxane (1.2 mL) and water (0.3 mL) at 130 
°C under microwave irradiation for 45 min gave the title compound (56 mg, 81%) as a colourless solid. LCMS (Method 
A, ES+): RT = 1.12 min (purity >96% at 254 nm), m/z Calcd for C25H32N5O3 [M+H]+ 450, found 450. ¹H NMR (300 
MHz, CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.85 (s, 0.4H), 7.74 (s, 0.6H), 7.37-7.13 (m, 5H), 
5.66-5.55 (m, 1H), 5.32-5.25 (m, 1H), 4.44-3.88 (m, 6H), 3.77-3.46 (m, 2H), 3.40-3.14 (m, 2H), 3.11-2.85 (m, 1H), 2.71-
2.57 (m, 1H), 2.57-2.41 (m, 1H), 2.27 (d, 3H), 1.66-1.21 (m, 6.4H), 0.93-0.74 (m, 0.6H). 
 
Compound 21: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-3-isopropyl-2-methyl-2,6-dihy-
dro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
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A solution of (R)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-(prop-1-en-2-yl)-2,6-dihy-
dro-7H-pyrazolo[4,3-d]pyrimidin-7-one (50 mg, 0.111 mmol) in MeOH (10 mL) was hydrogenated in an H-Cube® (10% 
Pd/C CatCart®, 1 mLmin-1, 50 °C, 60 bar H2). The resulting solution was concentrated under reduced pressure and the 
residue was purified by flash chromatography (Biotage KP-Sil 10 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH 
in EtOAc) to give the title compound (20 mg, 39%) as a colourless solid. LCMS (Method A, ES+): RT = 1.02 min (purity 
>98% at 254 nm), m/z Calcd for C25H34N5O3 [M+H]+ 452, found 452. ¹H NMR (300 MHz, CDCl3, this molecule appears 
as conformers in a 2:3 ratio): δ 7.70 (s, 0.4H), 7.59 (s, 0.6H), 7.38-7.15 (m, 5H), 4.48-4.26 (m, 1H), 4.19-3.83 (m, 5H), 
3.65-2.84 (m, 6H), 2.72-2.58 (m, 1H), 2.58-2.42 (m, 1H), 1.64-1.21 (m, 12.4H), 0.79-0.63 (m, 0.6H). 
 
Compound 22: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-(1H-pyrazol-5-yl)-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
N
NH
 
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (40 mg, 81.9 µmol), (1H-pyrazol-5-yl)boronic acid (27 mg, 0.246 mmol), 
K3PO4 (52 mg, 0.246 mmol), Pd(PPh3)4 (9 mg, 8.19 µmol), 1,4-dioxane (0.65 mL) and water (0.16 mL) at 150 °C under 
microwave irradiation for 10 min gave the title compound (26 mg, 66%) as a colourless solid. LCMS (Method A, ES+): 
RT = 0.97 min (purity >95% at 254 nm), m/z Calcd for C25H30N7O3 [M+H]+ 476, found 476. ¹H NMR (300 MHz, 
CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.87 (s, 0.4H), 7.81-7.71 (m, 1.6H), 7.39-7.15 (m, 6H), 
6.95 (br s, 1H), 4.46-3.90 (m, 6H), 3.77-3.47 (m, 2H), 3.44-2.88 (m, 3H), 2.72-2.42 (m, 2H), 1.79-1.24 (m, 6.4H), 0.97-
0.74 (m, 0.6H). 
 
Compound 23: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-phenyl-2,6-dihydro-
7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
 
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (40 mg, 81.9 µmol), phenylboronic acid (30 mg, 0.246 mmol), K3PO4 (52 
mg, 0.246 mmol), Pd(PPh3)4 (9.5 mg, 8.19 µmol), 1,4-dioxane (0.7 mL) and water (0.15 mL) at 150 °C under microwave 
irradiation for 10 min gave the title compound (31 mg, 77%) as a colourless solid. LCMS (Method A, ES+): RT = 1.23 
min (purity >98% at 254 nm), m/z Calcd for C28H32N5O3 [M+H]+ 486, found 486. ¹H NMR (300 MHz, CDCl3, this 
molecule appears as conformers in a 2:3 ratio): δ 7.84 (s, 0.4H), 7.73 (s, 0.6H), 7.65-7.44 (m, 5H), 7.39-7.14 (m, 5H), 
4.43-3.88 (m, 6H), 3.68-3.44 (m, 2H), 3.40-2.85 (m, 3H), 2.71-2.41 (m, 2H), 1.66-1.23 (m, 6.4H), 0.93-0.73 (m, 0.6H). 
 
Compound 24: (R)-3-(2-Fluorophenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
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General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (33 mg, 67.6 µmol), (2-fluorophenyl)boronic acid (28 mg, 0.203 mmol), 
K3PO4 (43 mg, 0.203 mmol), Pd(PPh3)4 (7.8 mg, 6.76 µmol), 1,4-dioxane (0.5 mL) and water (0.13 mL) at 150 °C 
under microwave irradiation for 10 min gave the title compound (24 mg, 70%) as a colourless solid. LCMS (Method A, 
ES+): RT = 1.23 min (purity >97% at 254 nm), m/z Calcd for C28H31FN5O3 [M+H]+ 504, found 504. ¹H NMR (300 
MHz, CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.86 (s, 0.4H), 7.74 (s, 0.6H), 7.61-7.44 (m, 2H), 
7.41-7.15 (m, 7H), 4.44-3.89 (m, 6H), 3.62-2.86 (m, 5H), 2.70-2.41 (m, 2H), 1.63-1.23 (m, 6.4H), 0.98-0.71 (m, 0.6H). 
 
Compound 25: (R)-3-(2-Aminophenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
ONH2
 
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (40 mg, 81.9 µmol), 2-aminophenylboronic acid hydrochloride (36 mg, 
0.205 mmol), K3PO4 (70 mg, 0.328 mmol), Pd(PPh3)4 (9.5 mg, 8.19 µmol), 1,4-dioxane (0.7 mL) and water (0.16 mL) 
at 150 °C under microwave irradiation for 10 min gave the title compound (33 mg, 80%) as a colourless solid. LCMS 
(Method A, ES+): RT = 1.14 min (purity >97% at 254 nm), m/z Calcd for C28H33N6O3 [M+H]+ 501, found 501. ¹H NMR 
(300 MHz, CDCl3, this molecule appears as conformers in a 2:3): δ 7.82 (s, 0.4H), 7.72 (s, 0.6H), 7.39-7.13 (m, 5H), 
7.13-7.05 (m, 1H), 6.93-6.57 (m, 3H), 4.40-3.84 (m, 6H), 3.62-2.84 (m, 5H), 2.70-2.41 (m, 2H), 1.64-1.24 (m, 6.4H), 
0.92-0.77 (m, 0.6H). 
 
Compound 26: (R)-3-(6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-7-oxo-6,7-dihydro-
2H-pyrazolo[4,3-d]pyrimidin-3-yl)benzonitrile 
N
NN
N
O
N
OH
O
CN  
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (33 mg, 67.6 µmol), (3-cyanophenyl)boronic acid (30 mg, 0.203 mmol), 
K3PO4 (43 mg, 0.203 mmol), Pd(PPh3)4 (7.8 mg, 6.76 µmol), 1,4-dioxane (0.5 mL) and water (0.13 mL) at 150 °C 
under microwave irradiation for 10 min gave the title compound (24 mg, 69%) as a colourless solid. LCMS (Method A, 
ES+): RT = 1.20 min (purity >95% at 254 nm), m/z Calcd for C29H31N6O3 [M+H]+ 511, found 511. ¹H NMR (300 MHz, 
CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.92-7.67 (m, 5H), 7.33-7.18 (m, 5H), 4.43-3.90 (m, 6H), 
3.65-2.86 (m, 5H), 2.72-2.41 (m, 2H), 1.66-1.23 (m, 6.4H), 0.92-0.77 (m, 0.6H). 
 
Compound 27: (R)-3-(3-Aminophenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
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General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (40 mg, 81.9 µmol), (3-aminophenyl)boronic acid (34 mg, 0.246 mmol), 
K3PO4 (52 mg, 0.246 mmol), Pd(PPh3)4 (9.5 mg, 8.19 µmol), 1,4-dioxane (0.65 mL) and water (0.16 mL) at 150 °C 
under microwave irradiation for 10 min gave the title compound (35 mg, 85%) as a colourless solid. LCMS (Method A, 
ES+): RT = 0.99 min (purity >96% at 254 nm), m/z Calcd for C28H33N6O3 [M+H]+ 501, found 501. ¹H NMR (300 MHz, 
CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.83 (s, 0.4H), 7.73 (s, 0.6H), 7.38-7.15 (m, 6H), 6.87-6.71 
(m, 3H), 4.42-3.71 (m, 8H), 3.59-3.43 (m, 1H), 3.42-3.11 (m, 2H), 3.09-2.82 (m, 1H), 2.71-2.40 (m, 2H), 1.93 (s, 1H), 
1.63-1.23 (m, 6.4H), 0.96-0.73 (m, 0.6H). 
 
Compound 28: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-3-(3-hydroxyphenyl)-2-methyl-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
OH  
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (32 mg, 65.5 µmol), (3-hydroxyphenyl)boronic acid (27 mg, 0.197 mmol), 
K3PO4 (42 mg, 0.197 mmol), Pd(PPh3)4 (7.6 mg, 6.55 µmol), 1,4-dioxane (0.5 mL) and water (0.13 mL) at 150 °C 
under microwave irradiation for 10 min gave the title compound (21 mg, 63%) as a colourless solid. LCMS (Method A, 
ES+): RT = 1.09 min (purity >98% at 254 nm), m/z Calcd for C28H32N5O4 [M+H]+ 502, found 502. ¹H NMR (300 MHz, 
methanol-d4, this molecule appears as conformers in a 2:3 ratio): δ 7.89 (s, 0.4H), 7.83 (s, 0.6H), 7.34-7.01 (m, 6H), 
7.00-6.89 (m, 2H), 6.89-6.78 (m, 1H), 4.19-3.70 (m, 6H), 3.66-3.47 (m, 1H), 3.26-2.31 (m, 5H), 1.60-1.08 (m, 6.4H), 
0.85-0.69 (m, 0.6H). 
 
Compound 29: (R)-3-(6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-7-oxo-6,7-dihydro-
2H-pyrazolo[4,3-d]pyrimidin-3-yl)benzamide 
N
NN
N
O
N
OH
O
CONH2  
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (40 mg, 81.9 µmol), (3-carbamoylphenyl)boronic acid (41 mg, 0.246 mmol), 
K3PO4 (52 mg, 0.246 mmol), Pd(PPh3)4 (9.5 mg, 8.19 µmol), 1,4-dioxane (0.65 mL) and water (0.16 mL) at 150 °C 
under microwave irradiation for 10 min gave the title compound (29 mg, 66%) as a colourless solid. LCMS (Method A, 
ES+): RT = 0.96 min (purity >96% at 254 nm), m/z Calcd for C29H33N6O4 [M+H]+ 529, found 529. ¹H NMR (300 MHz, 
CDCl3, this molecule appears as conformers a 2:3 ratio): δ 8.48-8.43 (m, 1H), 8.19 (s, 0.4H), 8.13-8.05 (m, 1.6H), 7.99-
7.93 (m, 1H), 7.63-7.54 (m, 1H), 7.39-7.17 (m, 5H), 6.97 (s, 1H), 4.51-3.79 (m, 3H), 3.66-3.48 (m, 1H), 3.45-2.81 (m, 
3H), 2.75-2.44 (m, 2H), 1.75-1.24 (m, 8.4H), 0.76-0.60 (m, 0.6H). 
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Compound 30: (R)-3-(3-((Dimethylamino)methyl)phenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-
yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
NMe2  
Step 1: (R)-3-(3-(Aminomethyl)phenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-
2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one: General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenyl-
butanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (90 mg, 0.184 mmol), (3-
(aminomethyl)phenyl)boronic acid hydrochloride (86 mg, 0.461 mmol), K3PO4 (156 mg, 0.737 mmol), Pd(PPh3)4 (21 
mg, 18.4 µmol), 1,4-dioxane (1.5 mL) and water (0.5 mL) at 150 °C under microwave irradiation for 10 min gave the 
title compound (30 mg, 31%) as a colourless solid. LCMS (Method B, ES+): RT = 0.75 min, m/z Calcd for C29H35N6O3 
[M+H]+ 515, found 515. 
 
Step 2: (R)-3-(3-((Dimethylamino)methyl)phenyl)-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-
2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one: To a mixture of (R)-3-(3-(aminomethyl)phenyl)-6-((4-hy-
droxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (30 mg, 
58.3 µmol) and paraformaldehyde (8.75 mg, 0.291 mmol) in ethanol (0.3 mL) was added NaBH4 (6.6 mg, 0.175 mmol) 
and the mixture was heated at reflux for 190 min. The reaction mixture was allowed to cool to rt before being diluted 
with brine (20 mL) and extracted with DCM (20 mL) using a Biotage phase separator. The organic phase was concen-
trated under reduced pressure and the residue was purified by flash chromatography (Biotage KP-NH 11 g cartridge, 0-
100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title compound (25 mg 79%) as a pale yellow solid. LCMS 
(Method B, ES+): RT = 0.77 min (purity >95% at 254 nm), m/z Calcd for C31H39N6O3 [M+H]+ 543, found 543. 1H NMR 
(500 MHz, DMSO-d6, this molecule appears as conformers in a 1:1 ratio): δ 8.00 (s, 0.5H), 7.97 (s, 0.5H), 7.64-7.56 (m, 
2H), 7.56-7.51 (m, 1H), 7.46-7.41 (m, 1H), 7.31-7.20 (m, 4H), 7.18-7.13 (m, 1H), 4.86 (s, 0.5H), 4.85 (s, 0.5H), 4.10 (s, 
3H), 4.06-3.87 (m, 4H), 3.68-3.61 (m, 1H), 3.50 (s, 2H), 3.25-3.12 (m, 2H), 2.93-2.83 (m, 1H), 2.61-2.55 (m, 1H), 2.19 
(s, 6H), 1.59-1.23 (m, 4H), 1.21 (d, 3H). 
 
Compound 31: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-3-(3-(morpholinome-
thyl)phenyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
N
O
N
OH
O
N O
 
General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (25 mg, 51.2 µmol), 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ben-
zyl)morpholine (39 mg, 0.128 mmol), K3PO4 (33 mg, 0.154 mmol), Pd(PPh3)4 (6 mg, 5.12 µmol), 1,4-dioxane (0.4 mL) 
and water (0.1 mL) at 130 °C under microwave irradiation for 15 min gave the title compound (19 mg, 63%) as a col-
ourless solid. LCMS (Method B, ES+): RT = 0.76 min (purity >95% at 254 nm), m/z Calcd for C33H41N6O4 [M+H]+ 
585, found 585. 1H NMR (500 MHz, DMSO-d6, this molecule appears as conformers in a 1:1 ratio): δ 8.00 (s, 0.5H), 
7.98 (s, 0.5H), 7.64 (s, 1H), 7.60 (d, 1H), 7.54 (t, 1H), 7.46 (d, 1H), 7.30-7.21 (m, 4H), 7.18-7.12 (m, 1H), 4.89 (s, 0.5H), 
4.87 (s, 0.5H), 4.11 (s, 3H), 4.14-3.86 (m, 4H), 3.70-3.53 (m, 6H), 3.27-3.13 (m, 2H), 2.92-2.83 (m, 1H), 2.66-2.55 (m, 
2H), 2.44-2.35 (m, 4H), 1.58-1.25 (m, 4H), 1.21 (d, 3H). 
 
Compound 32: (R)-4-(6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-7-oxo-6,7-dihydro-
2H-pyrazolo[4,3-d]pyrimidin-3-yl)benzamide 
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General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (25 mg, 51.2 µmol), (4-carbamoylphenyl)boronic acid (21 mg, 0.128 mmol), 
K3PO4 (33 mg, 0.154 mmol), Pd(PPh3)4 (6 mg, 5.12 µmol), 1,4-dioxane (0.4 mL) and water (0.1 mL) at 130 °C under 
microwave irradiation for 15 min gave the title compound (22 mg, 81%) as a colourless solid. LCMS (Method A, ES+): 
RT = 0.94 min (purity >95% at 254 nm), m/z Calcd for C29H33N6O4 [M+H]+ 529, found 529. 1H NMR (500 MHz, 
DMSO-d6, this molecule appears as conformers in a 1:1 ratio): δ 8.11 (s, 1H), 8.06 (d, 2H), 8.03 (s, 0.5H), 8.00 (s, 0.5H), 
7.82 (d, 2H), 7.49 (s, 1H), 7.30-7.21 (m, 4H), 7.19-7.13 (m, 1H), 4.88 (s, 0.5H), 4.87 (s, 0.5H), 4.15 (s, 3H), 4.05-3.89 
(m, 3H), 3.69-3.61 (m, 1H), 3.28-3.12 (m, 3H), 2.90-2.84 (m, 1H), 2.62-2.56 (m, 1H), 1.55-1.29 (m, 4H), 1.21 (d, Hz, 
3H). 
 
Compound 33: (R)-6-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-3-(4-(hydroxymethyl)phenyl)-2-
methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
N
NN
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General procedure 5 using (R)-3-bromo-6-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-2-methyl-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one1 (25 mg, 51.2 µmol), (4-(hydroxymethyl)phenyl)boronic acid (19 mg, 0.128 
mmol), K3PO4 (33 mg, 0.154 mmol), Pd(PPh3)4 (6 mg, 5.12 µmol), 1,4-dioxane (0.4 mL) and water (0.1 mL) at 130 °C 
under microwave irradiation for 15 min gave the title compound (19 mg, 71%) as a colourless solid. LCMS (Method A, 
ES+): RT = 1.01 min (purity >95% at 254 nm), m/z Calcd for C29H34N5O4 [M+H]+ 516, found 516. 1H NMR (500 MHz, 
DMSO-d6, this molecule appears as conformers in a 1:1 ratio): δ 7.99 (s, 0.5H), 7.97 (s, 0.5H), 7.69-7.65 (m, 2H), 7.54-
7.49 (m, 2H), 7.29-7.23 (m, 4H), 7.17-7.14 (m, 1H), 5.32 (t, 1H), 4.87 (s, 0.5H), 4.86 (s, 0.5H), 4.60 (d, 2H), 4.10 (s, 
3H), 4.07-3.87 (m, 3H), 3.69-3.61 (m, 1H), 3.27-3.13 (m, 2H), 2.92-2.83 (m, 1H), 2.66-2.55 (m, 2H), 1.57-1.28 (m, 4H), 
1.21 (d, 3H). 
 
Compound 35: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one 
N
N
O
N
OH
O  
Step 1: (R)-1-(3-Phenylbutanoyl)piperidin-4-one: To freshly prepared piperidin-4-one hydrochloride (Young, J., et 
al. WO 2011/084402 A1, Jul 14, 2011) (1.70 g, 12.6 mmol) was added EDC (2.89 g, 15.1 mmol), DMAP (153 mg, 1.26 
mmol), DCM (15 mL) and DIPEA (11 mL, 62.7 mmol). After 10 min a solution of (R)-3-phenylbutanoic acid (2.47 g, 
15.1 mmol) in DCM (10 mL) was added. After 20 h, EDC (2.89 g, 15.1 mmol) was added and the reaction stirred for a 
further 4 h. The reaction was quenched by the addition of saturated NaHCO3(aq) (150 mL) and the resulting mixture was 
extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with water (50 mL) and brine (50 mL) 
before being dried over MgSO4, concentrated under reduced pressure and the residue was purified by flash chromatog-
raphy (Biotage KP-Sil 50 g cartridge, 0-60% EtOAc in PE) to give the title compound (2.93 g, 95%) as a colourless oil. 
LCMS (Method A, ES+): RT = 1.07 min, m/z Calcd for C15H20NO2 [M+H]+ 246, found 246. ¹H NMR (300 MHz, 
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CDCl3): δ 7.44-7.13 (m, 5H), 4.30-4.03 (m, 1H), 3.77-3.58 (m, 1H), 3.46 (tdd, 2H), 3.11-2.93 (m, 2H), 2.82-2.61 (m, 
4H), 1.86 (m, 1H), 1.77-1.62 (m, 1H), 1.54-1.33 (m, 2H). 
 
Step 1: (R)-3-Phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)butan-1-one: To a solution of trimethylsulfonium iodide 
(6.09 g, 29.9 mmol) in DMSO (30 mL) was added NaH (1.19 g, 29.9 mmol). The resulting mixture was stirred at rt for 
1 h before a solution of (R)-1-(3-phenylbutanoyl)piperidin-4-one (2.93 g, 11.9 mmol) in DMSO (15 mL) was added. The 
reaction mixture was stirred at 50 °C for 2 h before it was allowed to cool to rt, quenched by the addition of water (100 
mL) and the resulting mixture was extracted with Et2O (3 x 50 mL). The combined organic phases were washed with 
brine (50 mL), dried over Na2SO4, concentrated under reduced pressure and the residue was purified by flash chroma-
tography (Biotage KP-Sil 50 g cartridge, 0-70% EtOAc in PE) to give the title compound (2.68 g, 87%) as a colourless 
oil. LCMS (Method A, ES+): RT = 1.16 min, m/z Calcd for C16H22NO2 [M+H]+ 260, found 260. ¹H NMR (300 MHz, 
CDCl3): δ 7.43-7.14 (m, 5H), 4.30-3.95 (m, 1H), 3.69-3.18 (m, 4H), 2.84-2.47 (m, 4H), 1.87-1.66 (m, 2H), 1.51-1.31 
(m, 2H), 1.37 (d, 3H). 
 
Step 3: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one: General procedure 
1 using pyrimidin-4(3H)-one (22 mg, 0.229 mmol), Cs2CO3 (94 mg, 0.289 mmol), (R)-3-phenyl-1-(1-oxa-6-
azaspiro[2.5]octan-6-yl)butan-1-one (50 mg, 0.193 mmol) and DMF (1 mL) gave the title compound (27 mg, 39%) as a 
white solid. LCMS (Method A, ES+): RT = 0.88 min (purity >99% at 254 nm), m/z Calcd for C20H26N3O3 [M+H]+ 356, 
found 356. 1H NMR (300 MHz, CDCl3): δ 7.92-8.10 (m, 2H), 7.25 (m, 5H), 6.52 (d, 1H), 4.25-4.50 (m, 1H), 3.48-4.06 
(m, 4H), 2.80-3.46 (m, 3H), 2.70 (m, 1H), 2.51 (m, 1H), 1.50 (m, 2H), 1.28 (m, 4H), 0.70 (m, 1H). 
 
Compound 36: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(methylamino)pyrimidin-
4(3H)-one 
N
N
O
N
OH
O
N
H
 
Step 1: (R)-6-Chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one: A suspen-
sion of 6-chloropyrimidin-4(3H)-one (200 mg, 1.53 mmol), (R)-3-phenyl-1-(1-oxa-6-azaspiro[2.5]octan-6-yl)butan-1-
one (397 mg, 1.53 mmol) and DIPEA (401 µl, 2.30 mmol) in DMF (3 mL) was heated at 80 °C for 16 h. The reaction 
mixture was allowed to cool to rt and quenched by the addition of saturated NH4Cl(aq) (20 mL). The resulting mixture 
was extracted with EtOAc (3 x 20 mL), the combined organic extracts were dried over Na2SO4, concentrated under 
reduced pressure and the residue was purified by flash chromatography (Biotage KP-Sil 25 g cartridge, 0-100% EtOAc 
in PE, then 0-30% MeOH in EtOAc) to give the title compound (350 mg, 59%) as a pale yellow solid. LCMS (Method 
A, ES+): RT = 1.11 min, m/z Calcd for C20H25ClN3O3 [M+H]+ 390, 392, found 390, 392. ¹H NMR (300 MHz, methanol-
d4, this molecule appears as conformers in a 2:3 ratio): δ 8.28 (s, 0.4H), 8.24 (s, 0.6H), 7.38-7.13 (m, 5H), 6.58 (s, 1H), 
4.27-4.09 (m, 1H), 4.00 (dd, 0.8H), 3.84 (dd, 1.2H), 3.74-3.57 (m, 1H), 3.39-2.86 (m, 3H), 2.86-2.67 (m, 1H), 2.66-2.43 
(m, 1H), 1.66-1.20 (m, 6.4H), 0.93-0.79 (m, 0.6H). 
 
Step 2: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(methylamino)pyrimidin-4(3H)-one: 
A solution of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (30 mg, 76.9 
µmol) in 2 M MeNH2 in THF (0.5 mL, 1.00 mmol) was heated at 130 °C under microwave irradiation for 1 h. The 
reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography (Biotage 
KP-NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title compound (23 mg, 77%) as 
a colourless solid. LCMS (Method A, ES+): RT = 0.84 min (purity >96% at 254 nm), m/z Calcd for C21H29N4O3 [M+H]+ 
385, found 385. ¹H NMR (300 MHz, CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.73 (s, 0.4H), 7.62 
(s, 0.6H), 7.37-7.15 (m, 5H), 5.30-5.23 (m, 1H), 5.11 (d, 1H), 4.49-4.30 (m, 1H), 4.03-3.47 (m, 3H), 3.42-3.16 (m, 2H), 
3.07-2.84 (m, 1H), 2.84 (d, 3H), 2.71-2.58 (m, 1H), 2.57-2.42 (m, 1H), 1.92 (br s, 1H), 1.60-1.10 (m, 6.4H), 0.67-0.52 
(m, 0.6H). 
 
Compound 37: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(phenylamino)pyrimidin-
4(3H)-one 
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N
N
O
N
OH
O
N
H
 
A solution of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (30 mg, 
76.9 µmol) in aniline (175 µL, 1.92 mmol) was heated at 130 °C under microwave irradiation for 1 h before the reaction 
mixture was purified directly by flash chromatography (Biotage KP-NH 11 g cartridge, 0-100% EtOAc in PE then 0-
30% MeOH in EtOAc) to give the title compound (22 mg, 64%) as a colourless solid. LCMS (Method A, ES+): RT = 
1.20 min (purity >95% at 254 nm), m/z Calcd for C26H31N4O3 [M+H]+ 447, found 447. ¹H NMR (300 MHz, methanol-
d4, this molecule appears as conformers in a 2:3 ratio): δ 8.23 (d, 0.4H), 8.08 (d, 0.6H), 7.43-6.92 (m, 10H), 6.56 (s, 
0.4H), 5.65 (s, 0.6H), 4.26-3.51 (m, 4H), 3.35-2.85 (m, 3H), 2.85-2.65 (m, 1H), 2.64-2.41 (m, 1H), 1.63-1.20 (m, 6.4H), 
0.95-0.73 (m, 0.6H). 
 
Compound 38: (R)-6-Benzyl-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one 
 
N
N
O
N
OH
O  
Step 1: tert-Butyl 4-((4-chloro-6-oxopyrimidin-1(6H)-yl)methyl)-4-hydroxypiperidine-1-carboxylate: A solution 
of 6-chloropyrimidin-4(3H)-one (3.72 g, 28.5 mmol), tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate1 (6.08 g, 28.5 
mmol) and DIPEA (7.47 mL, 42.7 mmol) in DMF (35 mL) was heated at 80 °C for 16 h. The reaction mixture was 
allowed to cool to rt before it was quenched by the addition of saturated NH4Cl(aq) (100 mL) and the resulting mixture 
was extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried over MgSO4, concentrated under 
reduced pressure and the residue was purified by flash chromatography (GraceResolv silica 120 g cartridge, 0-100% 
EtOAc in cyclohexane) to give the title compound (5.87 g, 60%) as an off-white solid. LCMS (Method B, ES+): RT = 
0.99 min, m/z Calcd for C15H23ClN3O4 [M+H]+ 344, 346, found 344, 346. 
 
Step 2: 6-Benzyl-3-((4-hydroxypiperidin-4-yl)methyl)pyrimidin-4(3H)-one:  A solution of tert-butyl 4-((4-chloro-
6-oxopyrimidin-1(6H)-yl)methyl)-4-hydroxypiperidine-1-carboxylate (60 mg, 0.174 mmol), potassium benzyltri-
fluoroborate (38 mg, 0.192 mmol) and triethylamine (36 µL, 0.26 mmol) in toluene (2 mL) and water (0.2 mL) was 
purged with N2 before PdCl2(dppf) (12.8 mg, 17.4 µmol) was added. The reaction tube was sealed and the mixture was 
heated at 110 °C for 16 h. The reaction was allowed to cool to rt, diluted with water (20 mL) and extracted into EtOAc 
(3 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash chromatography (GraceResolv silica 12 g cartridge; 10-100% EtOAc 
in cyclohexane, then 0-15% MeOH in EtOAc) to give a colourless glass. This was dissolved in DCM (1 mL) and TFA 
(1 mL) and stirred for 10 min before being concentrated under reduce pressure. The residue was dissolved in methanol 
and added to a 2 g SCX-2 cartridge. The column was flushed with MeOH before being eluted with 2 M NH3 in MeOH. 
The NH3 fractions were concentrated under reduced pressure to give the title compound (11 mg, 21%) as a colourless 
glass. LCMS (Method A, ES+): RT = 0.55 min, m/z Calcd for C17H22N3O2 [M+H]+ 300, found 300. 
 
Step 3: (R)-6-Benzyl-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one: General 
procedure 4 using 6-benzyl-3-((4-hydroxypiperidin-4-yl)methyl)pyrimidin-4(3H)-one (11 mg, 36.7 µmol), (R)-3-phe-
nylbutanoic acid (6.6 mg, 40.4 µmol), HATU (15.4 mg, 40.4 µmol), DIPEA (7.7 µL, 44.1 µmol) and DCM (1 mL) gave 
the title compound (11 mg, 67%) as a white solid. LCMS (Method B, ES+): RT = 1.14 min (purity >95% at 254 nm), m/z 
Calcd for C27H32N3O3 [M+H]+ 446, found 446. 1H NMR (300 MHz, DMSO-d6): δ 8.20 (d, 1H), 7.27 (m, 9H), 7.22 (m, 
1H), 6.21 (m, 1H), 4.92 (m, 1H), 3.86 (m, 2H), 3.76 (s, 3H), 3.60 (m, 1H), 3.14 (m, 2H), 2.80 (m, 1H), 2.55 (m, 2H), 
1.10-1.50 (m, 7H). 
 
Compound 39: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(phenylethynyl)pyrimidin-
4(3H)-one 
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N
N
O
N
OH
O
 
 
Step 1: 3-((4-Hydroxypiperidin-4-yl)methyl)-6-(phenylethynyl)pyrimidin-4(3H)-one: A solution of tert-butyl 4-
((4-chloro-6-oxopyrimidin-1(6H)-yl)methyl)-4-hydroxypiperidine-1-carboxylate (100 mg, 0.291 mmol), phenylacety-
lene (70 µL, 0.640 mmol) and trimethylamine (0.24 mL, 1.75 mmol) in DMF (1 mL) was purged with N2 before 
AuCl(PPh3) (7.2 mg, 14.5 µmol) and PdCl2(PPh3)2 (10.2 mg, 14.5 µmol) were added. The reaction tube was sealed and 
the reaction was heated at 60 °C for 16 h before being allowed to cool to rt. The mixture was diluted with water (20 mL) 
and extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (GraceResolv 12 g 
cartridge, 0-100% EtOAc in cyclohexane) to give an orange syrup. This was dissolved in DCM (1 mL) and TFA (1 mL) 
and stirred for 5 min before being concentrated under reduced pressure. The residue was dissolved in MeOH and added 
to a 2 g SCX-2 cartridge. The column was flushed with MeOH before being eluted with 2 M NH3 in MeOH. The NH3 
fractions were concentrated under reduced pressure to give the title compound (60 mg, 66%). LCMS (Method A, ES+): 
RT = 0.73 min, m/z Calcd for C18H20N3O2 [M+H]+ 310, found 310. 
 
Step 2: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(phenylethynyl)pyrimidin-4(3H)-one: 
General procedure 4 using 3-((4-hydroxypiperidin-4-yl)methyl)-6-(phenylethynyl)pyrimidin-4(3H)-one (58 mg, 0.187 
mmol), (R)-3-phenylbutanoic acid (33.9 mg, 0.206 mmol), DIPEA (0.043 mL, 0.244 mmol), HATU (82 mg, 0.216 mmol) 
and DCM (2 mL) gave the title compound (9 mg, 10%) as a colourless glass. LCMS (Method B, ES+): RT = 1.25 min 
(purity >95% at 254 nm), m/z Calcd for C28H30N3O3 [M+H]+ 456, found 456. 1H NMR (300 MHz, DMSO-d6): δ 8.28 
(d, 1H), 7.60 (d, 2H), 7.50 (m, 3H), 7.26 (m, 4H), 7.22 (m, 1H), 6.68 (m, 1H), 4.96 (m, 1H), 4.00 (m, 1H), 3.94 (m, 2H), 
3.71 (m, 1H), 3.21 (m, 2H), 2.90 (m, 1H), 2.55 (m, 2H), 1.05-1.55 (m, 7H). 
 
Compound 40: (R)-6-((2-(Dimethylamino)ethyl)amino)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)me-
thyl)pyrimidin-4(3H)-one 
N
N
O
N
OH
O
N
H
N
 
A mixture of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (25 mg, 
64.1 µmol), N,N-dimethylethylenediamine (85 mg, 0.962 mmol) and ethanol (0.5 mL) was heated at 120 °C under mi-
crowave irradiation for 20 min before the reaction mixture was purified directly by flash chromatography (Biotage KP-
NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title compound (22 mg, 77%) as a 
pale yellow solid. LCMS (Method A, ES+): RT = 0.60 min (purity >96% at 254 nm), m/z Calcd for C24H36N5O3 [M+H]+ 
442, found 442. ¹H NMR (300 MHz, CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.71 (s, 0.4H), 7.60 
(s, 0.6H), 7.36-7.15 (m, 5H), 5.68-5.58 (m, 1H), 5.29-5.23 (m, 1H), 4.49-4.32 (m, 1H), 4.00-3.48 (m, 3H), 3.43-3.07 (m, 
4H), 3.05-2.84 (m, 1H), 2.71-2.59 (m, 1H), 2.56-2.42 (m, 3H), 2.25 (s, 6H), 1.61-1.11 (m, 6.4H), 0.62-0.49 (m, 0.6H). 
 
Compound 41: (R)-6-(2-(Dimethylamino)ethoxy)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)me-
thyl)pyrimidin-4(3H)-one 
N
N
O
N
OH
O
O
N
 
A mixture of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (25 mg, 
64.1 µmol) and 2-(dimethylamino)ethanol (200 µL, 1.99 mmol) was heated at 150 °C under microwave irradiation for 
15 min before the reaction mixture was purified directly by flash chromatography (Biotage KP-NH 11 g cartridge, 0-
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100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title compound (17 mg, 59%) as a pale yellow solid. 
LCMS (Method A, ES+): RT = 0.58 min (purity >96% at 254 nm), m/z Calcd for C24H35N4O4 [M+H]+ 443, found 443. 
¹H NMR (300 MHz, CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.95 (s, 0.4H), 7.83 (s, 0.6H), 7.37-
7.16 (m, 5H), 5.78 (s, 1H), 4.47-4.23 (m, 3H), 4.11-4.02 (m, 0.6H), 3.90-3.69 (m, 1.4H), 3.64-3.49 (m, 1H), 3.42-3.16 
(m, 2H), 3.10-2.85 (m, 1H), 2.75-2.58 (m, 3H), 2.56-2.42 (m, 1H), 2.33 (s, 3H), 2.31 (s, 3H), 1.58-1.16 (m, 6.4H), 0.68-
0.52 (m, 0.6H). 
 
Compound 42: (R)-6-((2-(Dimethylamino)ethyl)(methyl)amino)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-
4-yl)methyl)pyrimidin-4(3H)-one 
N
N
O
N
OH
O
N
N
 
A mixture of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (25 mg, 
64.1 µmol), N,N,N′-trimethylethylenediamine (83 µL, 0.641 mmol) and 1,4-dioxane (0.5 mL) was heated at 150 °C under 
microwave irradiation for 15 min before the reaction mixture was purified directly by flash chromatography (Biotage 
KP-NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title compound (24 mg, 82%) as 
a pale yellow solid. LCMS (Method A, ES+): RT = 0.64 min (purity >96% at 254 nm), m/z Calcd for C25H38N5O3 
[M+H]+ 456, found 456. ¹H NMR (300 MHz, CDCl3, this molecule appears as conformers in a 2:3 ratio): δ 7.74 (s, 
0.4H), 7.63 (s, 0.6H), 7.36-7.15 (m, 5H), 5.38-5.30 (m, 1H), 4.50-4.33 (m, 1H), 4.00-3.17 (m, 8H), 3.08-2.84 (m, 4H), 
2.72-2.59 (m, 1H), 2.57-2.40 (m, 3H), 2.28 (d, 6H), 1.62-1.10 (m, 6.4H), 0.63-0.50 (m, 0.6H). 
 
Compound 43: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-((2-methoxyethyl)amino)py-
rimidin-4(3H)-one 
N
N
O
N
OH
O
N
H
O
 
A mixture of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (25 mg, 
64.1 µmol), 2-methoxyethanamine (56 µL, 0.641 mmol) and 1,4-dioxane (0.5 mL) was heated for 15 min at 150 °C 
under microwave irradiation. The reaction mixture was diluted with brine (15 mL) and extracted with DCM (10 mL) 
using a Biotage phase separator. The organic layer was concentrated under reduced pressure and the residue was purified 
by flash chromatography (Biotage KP-NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to afford 
the title compound (17 mg, 61%) as colourless solid. LCMS (Method A, ES+): RT = 0.85 min (purity >96% at 254 nm), 
m/z Calcd for C23H33N4O4 [M+H]+ 429, found 429. 1H NMR (500 MHz, DMSO-d6, this molecule appears as conform-
ers in a 1:1 ratio): δ 7.98 (s, 0.5H), 7.96 (s, 0.5H), 7.31-7.21 (m, 4H), 7.20-7.12 (m, 1H), 6.95 (s, 1H), 5.09 (s, 1H), 4.99 
(s, 0.5H), 4.99 (s, 0.5H), 4.03-3.94 (m, 1H), 3.84-3.58 (m, 4H), 3.42 (t, 2H), 3.25 (s, 3H), 3.28-3.12 (m, 3H), 2.93-2.86 
(m, 1H), 2.62-2.53 (m, 2H), 1.48-1.22 (m, 4H), 1.20 (d, 3H). 
 
Compound 44: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-((2-morpho-
linoethyl)amino)pyrimidin-4(3H)-one 
N
N
O
N
OH
O
N
H
N
O
 
A mixture of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (25 mg, 
64.1 µmol), 2-morpholinoethan-1-amine (84 µL, 0.641 mmol) and 1,4-dioxane (0.5 mL) was heated for 15 min at 150 
°C under microwave irradiation. The reaction mixture was diluted with brine (15 mL) and extracted with DCM (10 mL) 
using a Biotage phase separator. The organic layer was concentrated under reduced pressure and the residue was purified 
by flash chromatography (Biotage KP-NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to afford 
the title compound (25 mg, 80%) as pale yellow solid. LCMS (Method B, ES+): RT = 0.66 min (purity >98% at 254 nm), 
m/z Calcd for C26H38N5O4 [M+H]+ 484, found 484. 1H NMR (500 MHz, DMSO-d6): δ 8.01-7.93 (m, 1H), 7.31-7.21 
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(m, 4H), 7.20-7.13 (m, 1H), 6.74 (br s, 1H), 5.12-5.03 (m, 1H), 5.03-4.92 (m, 1H), 4.04-3.92 (m, 1H), 3.85-3.68 (m, 2H), 
3.66-3.58 (m, 1H), 3.59-3.52 (m, 4H), 3.28-3.09 (m, 4H), 2.95-2.85 (m, 1H), 2.62-2.53 (m, 2H), 2.46-2.42 (m, 2H), 2.41-
2.36 (m, 4H), 1.48-1.22 (m, 4H), 1.20 (d, 3H). 
 
Compound 45: (R)-6-((3-(Dimethylamino)propyl)amino)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-
yl)methyl)pyrimidin-4(3H)-one 
N
N
O
N
OH
O
N
H
N
 
A mixture of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (25 mg, 
64.1 µmol), N1,N1-dimethylpropane-1,3-diamine (81 µL, 0.641 mmol) and 1,4-dioxane (0.5 mL) was heated for 15 min 
at 150 °C under microwave irradiation. The reaction mixture was diluted with brine (15 mL) and extracted with DCM 
(10 mL) using a Biotage phase separator. The organic layer was concentrated under reduced pressure and the residue was 
purified by flash chromatography (Biotage KP-NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) 
to afford the title compound (24 mg, 82%) as pale yellow solid. LCMS (Method B, ES+): RT = 0.66 min (purity >97% 
at 254 nm), m/z Calcd for C25H38N5O3 [M+H]+ 456, found 456. 1H NMR (500 MHz, DMSO-d6): δ 7.99-7.90 (m, 1H), 
7.34-7.19 (m, 4H), 7.20-7.13 (m, 1H), 7.03-6.93 (m, 1H), 5.08-4.93 (m, 2H), 4.03-3.93 (m, 1H), 3.84-3.69 (m, 2H), 3.68-
3.58 (m, 1H), 3.26-2.96 (m, 4H), 2.94-2.85 (m, 1H), 2.61-2.52 (m, 2H), 2.27-2.17 (m, 2H), 2.13-2.07 (m, 6H), 1.68-1.57 
(m, 2H), 1.55-1.23 (m, 4H), 1.20 (d, 3H). 
 
Compound 46: (R)-3-((4-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-((2-(pyrrolidin-1-
yl)ethyl)amino)pyrimidin-4(3H)-one 
N
N
O
N
OH
O
N
H
N
 
A mixture of (R)-6-chloro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (25 mg, 64.1 
µmol), 2-(pyrrolidin-1-yl)ethanamine (81 μL, 0.641 mmol) and 1,4-dioxane (0.5 mL) was heated at 150 °C under mi-
crowave irradiation for 15 min before the reaction mixture was purified directly by flash chromatography (Biotage KP-
NH 11 g cartridge, 0-100% EtOAc in PE, then 0-30% MeOH in EtOAc) to give the title compound (22 mg, 73%) as a 
pale yellow solid. LCMS (Method A, ES+): RT = 0.61 min (purity >98% at 254 nm), m/z Calcd for C26H38N5O3 [M+H]+ 
468, found 468. 1H NMR (500 MHz, DMSO-d6): δ 8.06-7.93 (m, 1H), 7.37-7.19 (m, 4H), 7.19-7.13 (m, 1H), 6.79 (br s, 
1H), 5.05 (s, 1H), 5.00 (s, 1H), 4.02-3.94 (m, 1H), 3.86-3.68 (m, 2H), 3.66-3.58 (m, 1H), 3.25-3.10 (m, 4H), 2.94-2.86 
(m, 1H), 2.65-2.52 (m, 4H), 2.48-2.35 (m, 4H), 1.77-1.61 (m, 4H), 1.50-1.22 (m, 4H), 1.20 (d, 3H). 13C NMR (126 MHz, 
DMSO-d6): δ 169.0 + 169.0 (conformers), 161.9, 161.5, 152.2, 146.6 + 146.6 (conformers), 128.2 + 128.2 (conformers), 
126.8, 125.9 + 125.9 (conformers), 85.6 (very broad), 69.0 + 68.9 (conformers), 53.5, 52.8, 41.1 + 41.0 (conformers), 
40.3, 37.0, 36.1 + 36.0 (conformers), 35.0 + 34.9 (conformers), 34.3 + 34.2 (conformers), 23.1, 22.0 + 21.8 (conformers). 
HRMS (FTMS ES+): m/z Calcd for C26H38N5O3 [M+H]+ 468.2969, found 468.2963. 
 
3. USP7 surface plasmon resonance (SPR) 
Fragment Library Screening: 
SPR fragment library screening was performed by Beactica (Sweden) using Biacore 4000, S51 and T200 instruments 
(GE Healthcare/Biacore, Uppsala, Sweden). USP7 (His6-USP7CD (HAUSP cat domain), catalytic domain, aa 213-548, 
Boston Biochem, Lot # DBCW0111101) was immobilized by amine coupling using materials provided by GE 
Healthcare. The protein was prepared as a 0.1–0.2 mg/mL solution in coupling buffer (USP7: 50 mM acetate pH 5.5 
supplemented with 2 mM DTT, 0.5 mM EDTA) and injected for 5 min over activated surfaces (50 mM N-hydroxy-
succinimide, 200 mM N-ethyl-N´-((dimethylamino)propyl)carbodiimide) of CM7 or CM5 chips. The surfaces were sub-
sequently deactivated by 1 M ethanolamine, pH 8.0.  
Compound characterization: All interaction experiments were performed at 25 °C. Experiments were conducted in 
HBS buffer (10 mM HEPES, pH 7.4, 150 mM NaCl), supplemented with 0.05% Pluronic 127, 2 mM DTT, 0.5 mM 
EDTA and 5 % (v/v) DMSO (all Sigma). The test compounds were diluted in the running buffer in two- or three-fold 
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dilution series up to 300 μM and injected for 15-25 s over the immobilized Target Proteins as well as three Reference 
Targets (GST (Schistosoma japonicum, Sigma), anti-His antibody (Pierce), serine protease (Sprint™)). 
Data analysis: Report points from sensorgrams were extracted 5-15 s after initiation of the association phase. Re-
sponses were referenced with responses from unmodified reference surfaces, corrected for bulk shifts arising from dif-
ferences in DMSO concentrations between samples and running buffer (solvent correction) and blank-referenced. For 
competition analysis, responses of competitor-Test Compound mixtures were compared to the sum of responses of Test 
Compound and competitor alone. Competition values were determined as normalised deviation from theoretical re-
sponses for independent interaction (additivity of responses). Responses of mixtures 3 × σ lower or higher than predicted 
responses were classified as potential competitive or synergistic, respectively. For KD determination, the data was glob-
ally fitted to the sum of a Langmuir term and a linear term to compensate for non-specific binding using the Sprint™ 
evaluation software. 
SPR KD evaluation of compound 1: 
SPR KD evaluations were carried out on a SensíQ Pioneer instrument using COOH5 sensor chips, Qdat™ software 
and coupling reagents from Pall ForteBio. EDC (1-ethyl 3-(3-dimethylaminopropyl)-carbodiimide hydrochloride), sulfo-
NHS (sulfo-N-hydroxysuccinimide), sodium acetate pH4.5 and ethanolamine pH8.9 were from GE Health Sciences. 
Catalytic domain USP7 was procured from Boston Biochem. 
A COOH5 sensor chip was installed in the SensíQ Pioneer system, normalized with air, followed by DMSO, and 
primed with running buffer (10 mM HEPES, 150 mM NaCl, pH 7.4; HBS).  Catalytic domain of USP 7 was immobilized 
at 25 ºC onto a COOH5 sensor chip using standard amine-coupling methods and HBS as the running buffer. The surface 
was activated with 0.5 mM EDC and 0.2 mM sulfo-NHS for 5 min, followed by a 12-min injection of USP7 CD at 100 
µg/mL in 10 mM sodium acetate, pH 4.5, and finally a 5-min blocking step of 1 M ethanolamine, pH 8.9. This coupling 
method resulted in a density of 9,000 RU (resonance units) of USP7 on one flow cell of the COOH5 chip. OneStep 
screening using Taylor dispersion concentration gradient of compound 1 at concentrations in a three-fold dilution series 
starting at 5 mM were completed at a flow rate of 75 µL/min for 60 s.  The response data were processed using Qdat™ 
software using a reference surface to correct for any bulk refractive index changes and blank injections for double refer-
encing. The binding profiles were fitted globally to a 1:1 interaction model. 
 
4. USP7 NMR-binding studies: 
Human USP7 catalytic domain (amino acids 208-555, Crelux GmbH) was delivered in PBS (137 mM NaCl, 2.7 mM 
KCl, 1 mM NaH2PO4/Na2HPO4), pH 7.4 at a concentration of 13.9 mg/mL (331 μM). The protein was cloned and 
expressed in E. coli using an N-terminal 6-histidine tag. Purification of cell lysate was performed by Ni-NTA column, 
followed by Superdex size exclusion chromatography (SEC). Purity was determined to be >85% using SDS page. 
Reference 1H spectrum for compound 1 was collected at 1 mM concentration, formulated in PBS buffer identical to 
that the protein was supplied in. The compound tested negative for self-aggregation using the WaterLOGSY pulse se-
quence with no macroscopically visible precipitate or diminished signals in the proton spectrum. Compound 1 was in-
cluded in a cocktail of other compounds, including a positive and negative control. The cocktail was comprised of 10 
μM USP7 and a total of 6 compounds at a concentration of 200 μM each, resulting in a 1:20 USP7:compound ratio. Each 
cocktail was subjected to a trio of 1H, ligand-observed experiments, namely saturation transfer difference (STD), Carr-
Purcell-Meiboom-Gill (CPMG) T2, and WaterLOGSY experiments. 
NMR Hardware and Processing: All experiments were performed in-house on a 500 MHz Bruker AVANCE spectrom-
eter equipped with TCI Cryoprobe, using standard pulse programs included in Bruker’s experiment library. Spectra were 
collected at 25 °C, and processed using Bruker’s TopSpin software program. 
 
5. Biochemical and cellular assays: 
The USP7 biochemical assay was performed using materials and conditions outlined in reference 1. 
 
Target Engagement Assay in HCT116 Cells 
HCT116 cells were treated with vehicle (DMSO) or USP7 inhibitor for 2 h. Following incubation, cells were washed 
extensively with 1 x PBS and harvested in TE lysis buffer containing 50 mM TRIS-HCl (pH7.4), 150 mM NaCl, 5 mM 
MgCl2, 0.5 mM EDTA, 0.5% NP40, 10% Glycerol, 2 mM DTT and clarified cell lysates (40 µg) incubated with the 
ubiquitin-propargylamine probe (Ub-PA; 8 µg/ml final concentration) in assay buffer containing 50 mM TRIS-HCl 
(pH7.6), 5 mM MgCl2, 250 mM Sucrose, 0.5 mM EDTA, 2 mM DTT for 30 min. The reaction was terminated by the 
addition of LDS sample buffer (Life Technologies) and heated to 70 oC. Samples were then analyzed by western blotting 
using the Cell Signalling anti-USP7 Ab (#4833; 1/1000 dilution). EC50 values were determined upon densitometry anal-
ysis. Band intensities were quantified using ImageJ software where the upper bands (USP7-Ub) and lower 
bands (USP7) were calculated as a percentage of the corresponding DMSO controls (-/+ Ub-PA) and values were then 
normalized to the sum of the lower and upper bands for each concentration. 
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6. DUB selectivity assay on compound 46: 
Selectivity assays were performed against all USPs included in the DUBprofiler™ panel (Ubiquigent Ltd). Screening 
was performed at a fixed inhibitor concentration of 10 µM. Data generated is displayed as a percentage inhibition of total 
enzyme activity for each enzyme. Under the conditions of this screen, 46 exhibited an IC50 value of 140 ± 22 nM. Data 
reported as the mean of 2 independent experiments. 
 
7. Protein production, crystallization, data collection and structure determination: 
The USP7 catalytic domain (residues 207-560), genetically fused with a C-terminal hexa-histidine tag, was expressed 
in E.coli.  BL21 cells were transformed with the corresponding expression plasmid and grown in Terrific broth (TB) and 
protein expression induced with 0.25 mM IPTG overnight at 16°C. After harvesting by centrifugation, cell pellets were 
resuspended in Lysis Buffer (40 mM TRIS-HCl, 500 mM NaCl, 1 mM AEBSF, 2 mM TCEP, 5 mM Imidazole, 0.1% 
Tween 20, pH 7.5) and lysed by sonication on ice. The soluble fraction was then loaded directly onto an IMAC column 
(5 mL HisTrap HP) pre-equilibrated with Lysis Buffer and the protein eluted with IMAC Buffer B (40 mM TRIS-HCl, 
500 mM NaCl, 1 mM AEBSF, 2 mM TCEP, 300 mM Imidazole, 0.1% Tween 20, pH 7.5). Fractions containing the 
desired protein were pooled and buffer exchanged by disalysis (MWCO 8,000-10,000 Da) against anion exchange (AEX) 
Buffer A (20 mM TRIS-HCl, 30 mM NaCl, 1 mM EDTA, 4 mM DTT, pH 8.0). 
The protein was then loaded onto a YMC-BioPro ion exchange column (15 x 120, 7.4 mL) pre-equilibrated with AEX 
Buffer A and eluted over 30 CV with a gradient of 0-50% AEX Buffer B  (20 mM TRIS-HCl, 1M NaCl, 1 mM EDTA, 
4 mM DTT, pH 8.0). 
Fractions were analyzed by SDS-PAGE and those containing the desired protein were pooled and then further purified 
by SEC (HighLoad Superdex 75 column) using a running buffer of 10 mM TRIS-HCl, 100 mM NaCl, 4 mM DTT, pH 
8. SEC fractions were analyzed by SDS-PAGE and the pure fractions pooled and concentrated (Vivaspin column, MWCO 
12KDa) to 5.3 mg / mL as measured by UV A280nm. 
 Crystals of USP7 in complex with 46 were grown by hanging drop vapour diffusion. USP7 (14.2 mg/ml in 10 mM 
TRIS-HCl, 100 mM NaCl, 4mM TCEP, pH 8.0) was pre-incubated with an 8.9-fold molar excess of 46 (150 mM in 
DMSO) for 2 h. 0.7 µl of the protein solution was then mixed with 0.7 µl of reservoir solution containing 100 mM TRIS-
HCl (pH 7.75), 200 mM Li2SO4, 25% (w/v) PEG4000 and equilibrated at 20°C over 0.4 mL of reservoir solution. Crys-
tals appeared within 4 days. 
Diffraction data at 2.2 Å resolution for a USP7/46 crystal was collected at the ESRF synchrotron radiation source, 
id30a1, Grenoble. The structure was solved via molecular replacement using the PDB structure 5N9R as a template. 
Iterative manual modelling in Coot and refinement using REFMAC5 resulted in the final model. 97.5% of backbone 
torsions for the final model are within the Ramachandran favoured regions, with 2.5% in the allowed regions. The crys-
tallography data collection and refinement statistics are provided in Supplementary Table 1 below. 
 
Data collection statistics 
Space group P21 
Unit cell 
a, b, c (Å) 
α, β, γ, (°) 
 
74.9. 67.3, 80.7 
90, 105.1, 90 
# molecules per au 2 
Resolution (Å) 28.22-2.16 (2.28-2.16) 
# unique reflections 39952 (5872) 
Completeness (%) 95.9 (96.8) 
Redundancy 2.4 (2.4) 
Rmerge 0.110 (0.670) 
I/σ 6.4 (1.4) 
Refinement statistics 
Resolution (Å) 29.95-2.16 (2.22-2.16) 
Rwork / Rfree 0.202 / 0.262 
Supplementary Table 1. Crystallography data collection and refinement statistics for compound 46 and USP7 
 
8. In vitro ADME & physicochemical methods: 
 
Kinetic Solubility: 
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Test compounds (5 μL; 10 mM DMSO stock) were added to 245 μL of PBS buffer pH 7.4 (Dulbecco A) in a Millipore 
MultiScreen® Solubility Filter plate and mixed at 300 rpm at rt on a plate shaker for 90 min. Meanwhile 5-points cali-
bration curves for each compound were established in a mixture of acetonitrile/PBS buffer (top concentration 200 μM). 
After filtration and matrix match, the calibration and assay plates were analyzed on a Bioteck Synergy 4 plate reader 
(240-400 nm). Final concentration of the test compound in the filtrate was calculated using the slope of the calibration 
curve. Two markers were used as controls: hydrocortisone (high solubility KSol >180 μM) and reserpine (low solubility 
KSol < 25 μM). 
 
Caco-2 permeability: 
Caco-2 permeability measurements were performed at Cyprotex Ltd. Caco-2 cells obtained from the ATCC are used 
between passage numbers 40-60. Cells are seeded on to Millipore Multiscreen Caco-2 plates at 1 x 105 cells/cm2. They 
are cultured for 20 days in DMEM and media is changed every two or three days. On day 20 the permeability study is 
performed.  
Hanks Balanced Salt Solution (HBSS) pH 7.4 buffer with 25 mM HEPES and 4.45 mM glucose at 37 °C is used as 
the medium in the permeability studies. Incubations are carried out in an atmosphere of 5% CO2 with a relative humidity 
of 95% at 37 °C.  
On day 20, the monolayers are prepared by rinsing both basolateral and apical surfaces twice with HBSS at 37 °C. 
Cells are then incubated with HBSS in both apical and basolateral compartments for 40 min to stabilise physiological 
parameters.  
HBSS is then removed from the apical compartment and replaced with test compound dosing solutions. The solutions 
are made by diluting 10 mM test compound in DMSO with HBSS to give a final test compound concentration of 10 μM 
(final DMSO concentration 1%). The fluorescent integrity marker Lucifer yellow is also included in the dosing solution. 
Analytical standards are made from dosing solutions. The apical compartment inserts are then placed into ‘companion’ 
plates containing fresh HBSS. For basolateral to apical (B-A) permeability determination the experiment is initiated by 
replacing buffer in the inserts then placing them in companion plates containing dosing solutions. At 120 min, the com-
panion plate is removed and apical and basolateral samples diluted for analysis by LC-MS/MS. Test compound permea-
bility is assessed in duplicate. On each plate compounds of known permeability characteristics are run as controls.  
Test and control compounds are quantified by LC-MS/MS cassette analysis using a 5-point calibration with appropriate 
dilution of the samples. Cyprotex generic analytical conditions are used. The starting concentration (C0) is determined 
from the dosing solution and experimental recovery calculated from C0 and both apical and basolateral compartment 
concentrations. 
The integrity of the monolayers throughout the experiment is checked by monitoring Lucifer yellow permeation using 
fluorimetric analysis. Lucifer yellow permeation is low if monolayers have not been damaged. If a Lucifer yellow Papp 
value is above QC limits in one individual test compound well, then an n=1 result is reported. If Lucifer yellow Papp 
values are above QC limits in both replicate wells for a test compound, the compound is re-tested. If on repeat, high 
Lucifer yellow permeation is observed in both wells then toxicity or inherent fluorescence of the test compound is as-
sumed. No further experiments are performed in this instance.  
 
Data Analysis:  
The permeability coefficient for each compound (Papp) is calculated from the following equation:  
 
 
 
Where dQ/dt is the rate of permeation of the drug across the cells, C0 is the donor compartment concentration at time 
zero and A is the area of the cell monolayer. C0 is obtained from analysis of dosing solution at the start of the experiment. 
An efflux ratio (ER) is derived as follows:  
 
An efflux ratio greater than two shows efflux from the Caco-2 cells, which indicates that the compound may have 
potential absorption problems in vivo.  
The apparent permeability (Papp (A-B)) values of test compounds are compared to those of control compounds, atenolol 
and propranolol, which have human absorption of approximately 50 and 90% respectively. Talinolol (a known P-gp 
substrate2) is also included as a control compound to assess whether functional P-gp is present in the Caco-2 cell mono-
layer. 
 
LogD7.4: 
 
 
24 
Test compounds (8 μL; 10 mM DMSO stock) was added to 392 μL of PBS buffer pH 7.4 (Dulbecco A pre-saturated 
with octanol) and 400 μL of octanol (pre-saturated with PBS buffer). The plate was shaken at rt for 4 h. The layers were 
allowed to separate before being analyzed by HPLC.  
Samples were analyzed on an Agilent 1260 HPLC fitted with a Phenomenex Kinetex XB-C18 100A 2.6 μm 2.1x50 
mm column. Mobile phases were water and acetonitrile containing 0.1% formic acid as modifier. The relative drug 
concentration in each phase was determined by the peak area measurement from LC-UV analysis, UV detection at 254 
nm and 210 nm.  
Log D7.4 is calculated as follows: 
 
Three markers were used as controls: caffeine (LogD7.4 ~ 0), furosemide (LogD7.4 < - 0.5) and reserpine (LogD7.4 > 3). 
 
Microsomal stability: 
Test compounds (final concentration = 1 μM; final DMSO concentration = 0.1%) were incubated in 0.1 M phosphate 
buffer pH 7.4 with liver microsomes (human, mouse or rat; 0.5 mg of protein/mL) at 37 °C. Reactions were started by 
addition of NADPH in 0.1 M phosphate buffer pH 7.4 (final concentration 1 mM). 40 μL aliquots were removed at 2, 5, 
10, 15, 20, 30, 40 and 50 min. Reactions were quenched in 80 μL of ice-cold methanol containing internal standard. 
Samples were subsequently frozen overnight then centrifuged at 3500 rpm for 20 min at 4 °C. The supernatants were 
removed and transferred into analytical plates and analyzed by LC-MS/MS.  
LC-MS/MS method: All samples were analyzed on a Waters Acquity I-Class coupled to a Waters Xevo TQD mass 
spectrometer. A Waters BEH C18 2.1 x 50 mm 1.7 μm column was used and mobile phases were water and methanol 
containing 0.1 % formic acid as modifier. Analysis was by multiple reaction monitoring and conditions were optimised 
for each test compound.  
Data analyses: From a plot of ln peak area against time, the gradient of the line is determined. Subsequently, half-life 
and intrinsic clearance are calculated using the equations below:  
 
Eliminated rate constant (k) = (- gradient)  
 
Half-life (t½) (min) =  
0.693
𝑘𝑘
 
 
Intrinsic Clearance (CLint)(μL/min/mg protein) = 𝑉𝑉 𝑥𝑥 0.693
𝑡𝑡½  
 
Where V = Incubation volume (μL)/mg of protein  
 
Four markers were used as controls for each assay: 
 
Human Liver Microsomes  Dextromethorphan  Moderate-high CLint  
 Quinidine  Low-moderate CLint  
 Tolbutamide  Low CLint  
 Verapamil  High CLint  
Mouse Liver Microsomes  Diphenydramine  High CLint  
 Metroprolol  Low-moderate CLint  
 Diclofenac  Moderate CLint  
 Verapamil  High CLint  
 
 
9. Pharmacokinetic Profiling of Compounds 46 & 47: 
Pharmacokinetics of compounds 46 and 47 were evaluated in healthy male CD-1 mice following a single oral, intra-
venous or intraperitoneal administration. Dosing solutions for intravenous administration were prepared using DMSO: 
20% 2-hydroxypropyl β cyclodextrin (2:98) and administered at a dose level of 1 mg/kg. Dosing solutions for oral ad-
ministration were prepared using 0.5 % methylcellulose and administered at a dose level of 30 mg/kg. Dosing solutions 
for intraperitoneal administration were prepared using saline and administered at a dose level of 10 mg/kg. Blood samples 
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were collected up to 24 h post-dose. In-vivo experiments were carried out at Axis BioServices and pharmacokinetic 
parameters were measured from blood by XenoGesis Ltd. 
 
A total of 27 male CD-1 mice aged 5-8 weeks, weighing approximately 30-35g were used for the study (animals were 
bred in-house at Axis BioServices). Mice were housed in IVC cages (5 per cage) with individual mice identified by tail 
mark. The holding room was maintained under standard conditions: 20-24 °C, 40-70 % humidity and a 12 h light/dark 
cycle. Animals were fed a standard certified commercial laboratory rodent diet except for overnight fasting immediately 
prior to dosing; animals were allowed access to food 2 hours after test compound administration. Animals were allowed 
free access to water at all times during the study. 
Dosing solutions were freshly prepared as follows: 
For IV dosing solutions:  
1.0 mg compound 46 was weighed and mixed with DMSO (40 μL). 1960 μL of 20% 2-hydroxypropyl β cyclodextrin 
was added to give a final concentration of 0.5 mg/mL. 
1.3 mg compound 47 was weighed and mixed with DMSO (52 μL). 2548 μL of 20% 2-hydroxypropyl β cyclodextrin 
was added to give a final concentration of 0.5 mg/mL. 
 
For PO dosing solutions:  
12.2 mg compound 46 was weighed and mixed with 1mL 0.5% methylcelluose with a pestle and mortar. A further 1.03 
mL 0.5% methylcellulose was used to completely wash any compound into the tube, giving a final concentration of 6 
mg/mL. 
15.2 mg compound 47 was weighed and mixed with 1mL 0.5% methylcelluose with a pestle and mortar. A further 
1.533 mL 0.5% methylcellulose was used to completely wash any compound into the tube, giving a final concentration 
of 6 mg/mL. 
 
For IP dosing solutions: 
 4.5 mg compound 46 was weighed and mixed with 1mL sterile saline with a pestle and mortar. A further 3.5 mL saline 
was added to completely wash any compound into the tube, giving a final concentration of 1 mg/mL. 
3.8 mg compound 47 was weighed and mixed with 1mL sterile saline with a pestle and mortar. A further 2.8 mL saline 
was added to completely wash any compound into the tube, giving a final concentration of 1 mg/mL. 
 
The dosing volumes were 2 mL/kg for IV dosing, 5 mL/kg for PO dosing and 10 mL/kg for IP dosing with individual 
dose calculated from the bodyweight recorded on the day of dosing. At the required time points 100 uL whole blood was 
removed from the lateral vein into tubes coated with K2-EDTA. Blood samples were diluted 1:1 with ultrapure water 
and stored at -80°C before being transported to XenoGesis Ltd on dry ice for bioanalysis. The time points for blood 
sampling were 5min, 15min, 30min, 1h, 2h, 4h, 8h and 24h for the IV and IP routes. They were 15min, 30min, 1h, 2h, 
4h, 6h, 8h and 24h for the PO route. PK parameters were calculated using Phoenix WinNonlin software. 
 
10. Computational Chemistry: 
Docking studies and images were carried out or created using Molecular Operating Environment (MOE, 2015.1001 or 
2016.0802; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7 
(2017)) and/or Maestro (Schrödinger Release 2016-4: Maestro, Schrödinger LLC, New York, NY (2016). 
 
11. Supporting Figure S1: USP7 SPR sensogram of compound 1: 
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12. Supporting Figure S2: USP7 NMR spectra of compound 1: 
 
 
Figure S2: A-C Aromatic region expansion of 1D 1H NMR spectra illustrating binding of compound 1 to USP7 in 
cocktail containing 10 μM USP7, 200 μM compound 1 in PBS pH 7.4, collected at 25 °C.  A. Cocktail reference (black 
trace) and saturation transfer difference spectra (STD, red trace) illustrating positive STD signal of compound 1, indi-
cated by asterisks. B. Reference (black trace) and T2 Carr-Purcell-Meiboom-Gill (CPMG, green trace) spectra illustrating 
line broadening of signals of compound 1. C. WaterLOGSY spectrum (black trace) of cocktail illustrating binding of 
compound 1. D. Aromatic region expansion of reference 1D 1H NMR spectrum (blue trace) of 1 mM compound 1 in 
PBS pH 7.4. 
 
13. Supporting Figure S3: Structure of trifluromethyl analogue 47: 
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